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The squamous cell carcinoma (SCC) is a major cause of cancer mortality. The 
carcinogenesis of this tumor is linked to a series of molecular derangements that 
frequently features the deregulation of RHO GTPase signaling. However, the events 
and agents underpinning such deregulation are yet to be defined. RHO exchange 
factors (GEFs), the proteins that catalyze the activation of RHO GTPases, have been 
traditionally contemplated as potential protumorigenic players in this context, but 
their large numbers and the lack of appropriate models has precluded the elucidation 
of their true functions in cancer settings. To address this issue, in this thesis we have 
focused on VAV2 to spearhead the characterization of RHO GEFs as key mediators 
of tumorigenesis and, more importantly, as candidate targets for novel SCC-directed 
therapeutic approaches. Here we demonstrate that VAV2 becomes upregulated in 
cutaneous and head-and-neck SCCs, where it engages a transcriptional program 
involved in the induction of stem cell-like regenerative proliferation and 
undifferentiation. Significantly, we show that VAV2 activity predicts disease 
outcome and that its inhibition within specific catalytic thresholds provides 
antitumoral benefits without disturbing organismal homeostasis. This work also 
exposes non-oncogenic roles for this GEF in the physiological maintenance of the 
cutaneous squamous epithelium, where it regulates the abundance, activity and 
responsiveness of hair follicle stem cells through the control of their transcriptomic 
circuits. Lastly, by extending these studies to the whole family of RHO GEFs, our 
research shows that VAV2 belongs to a small collection of exchange factors with 
pivotal roles in either the promotion or impairment of SCC tumorigenesis-associated 
processes. Taken together, our findings unveil hitherto unknown regulators of SCC 
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1. PHYSIOLOGY OF THE STRATIFIED SQUAMOUS 
EPITHELIUM 
1.1. STRUCTURE AND FUNCTION 
The stratified squamous epithelium is one of the most abundant epithelia of the 
human body. It is fundamentally composed of several layers of stacked cells 
arranged along an apical-basal axis resting on a basement membrane. Suited to 
endure constant abrasion, this epithelium covers the outermost layers of different 
organs, including the skin, the inner lining of the mouth, the esophagus and the 
vagina. Among these, the skin contains arguably the most illustrative representative 
of this kind of epithelium: the epidermis (Figure I). 
Figure	I	
	
FIGURE I. Structure of the epidermis. Schematic representation (left) and example of a 
histological section stained with hematoxylin and eosin (right) of the epidermis. The span of the 
different strata (St.) that compose the epidermal tissue is indicated. Adapted from [1]. 
 
The epidermis is primarily made up of keratinocytes, epithelial cells that 
constitute different strata from the bottom to the top of the epithelium: the stratum 
basale, the stratum spinosum, the stratum granulosum and the stratum corneum 
(Figure I). Mature keratinocytes are continuously sloughed from the epidermal 
surface and replaced by younger cells emerging from deeper layers, making the 
epidermis one of the tissues with the highest self-renewal rates [1]. The maintenance 
of such balance requires a tightly regulated cell proliferation activity, a process that 
takes place in the deepest epidermal layer, the stratum basale (Figure I). Here, 














between proliferating and quiescent states [2]. When these cells divide, daughter 
cells detach from the basement membrane and embark on a journey towards the 
epidermal surface as they follow a terminal differentiation program known as 
keratinization. 
The cells that leave the stratum basale firstly give rise to the stratum 
spinosum (Figure I). These polyhedral keratinocytes are tightly bound to one 
another through the establishment of abundant desmosomes, which gives them their 
‘spiny’ appearance. It is at this stratum where the synthesis of certain groups of 
cytokeratins, lipids and enzymes involved in the keratinization process starts [3, 4].  
On top of this layer flattened keratinocytes accumulate keratohyalin and 
lamellar granules, forming the stratum granulosum (Figure I). Keratohyalin granules 
contain mainly filaggrin and loricrin, which work in concert with other proteins 
involved in keratinocyte differentiation such as involucrin and transglutaminases. 
Lamellar bodies, on the other hand, contain primarily ceramides and cholesterol 
esters, which are required to regulate the permeability of the epidermal epithelium [3, 
4].  
In their last differentiation stage, keratinocytes go through a number of 
processes that dramatically change their cellular identity: i) they lose their nucleus 
and cytoplasm, ii) their keratin filaments aggregate into microfibrils, iii) their lipids 
are released into the intercellular space and iv) their plasma membrane is replaced by 
a cross-linked protein envelope. The resulting fully mature keratinocytes, also termed 
corneocytes, are the ones that compose the outermost epidermal layer, the stratum 
corneum (Figure I). The conjunction of the densely packed keratin and the cross-
linked cell envelope makes this stratum a highly resistant barrier, which is 
impermeabilized by the lipidic component found in the intercellular space. This 
structure is held together by desmosomes, whose eventual proteolytic cleavage leads 
to the desquamation of the corneocyte, drawing the life cycle of the epidermal cell to 
an end [3, 4]. 
The epidermis is not the only stratified squamous epithelium with this 
architecture. Despite appearances, the oral mucosa has more in common with the 
epidermis than with the epithelial lining of rest of the gastrointestinal tract [5]. In 














palate and gingiva) and specialized (dorsal surface of the tongue) mucosae, the 
epithelium is keratinized and histologically very similar to the epidermis [6]. 
Both the epidermis and the oral mucosa are also populated by non-epithelial 
cells, such as melanocytes, Merkel cells and Langerhans cells. Melanocytes are 
neural crest-derived melanin-producing cells that reside in the stratum basale and 
protect keratinocytes from ultraviolet radiation [7]. Also located in the basal layer 
and in close proximity to nerve tissue, Merkel cells participate in the 
mechanoreception responsible for touch sensing [8]. Lastly, lodged in the stratum 
spinosum, the bone marrow-derived Langerhans cells perform antigen presentation 
to T-cells, thus providing immunological protection to the epithelium [9].  
The conjunction of all these cell types and structures makes the squamous 
epithelium a physically-, chemically-, and biologically-competent barrier with key 
roles in thermoregulation, water loss prevention and sensorial perception. 
 
1.2. MOLECULAR REGULATION 
1.2.1. Undifferentiation and proliferation 
The homeostatic maintenance of the squamous epithelium is regulated by a vast 
signaling network that orchestrates keratinocyte division and maturation in a stratum-
specific manner [10] (Figure II). In the basal layer, the undifferentiated and 
proliferative states are maintained by the transcription factor p63 [11]. This protein is 
an essential regulator of all squamous specification, since its loss prevents the 
development of every stratified epithelia of the body [12]. Basal keratinocyte 
homeostasis also requires other key regulators such as: i) c-Myc, which stimulates 
proliferation and regulates differentiation in a dosage-dependent manner [13], ii) the 
yes-associated protein (YAP), involved in the maintenance of the progenitor-like 
undifferentiated state [14], and iii) AP1, which regulates proliferation and 
differentiation at different maturation stages [15, 16].  
The basal balance between differentiation and proliferation is further 
controlled by the mitogen-activated protein kinase (MAPK) cascade (Figure II). 
Loss of Mek1/2 [17] or Erk1/2 [18] signaling results in epidermal hypoplasia, while 
the activation of Ras, Raf or Mek1 leads to hyperplasia and reduced differentiation 














tyrosine kinase receptors, such as the epidermal growth factor receptor (EGFR). On 
the other hand, adhesion molecules such as cadherins and catenins are responsible 
for its downmodulation [10]. 
Figure	II	
 
FIGURE II. Molecular determinants of the epidermal development. Schematic representation of 
the epidermal tissue along with the differentiation markers and signaling elements that characterize 
each maturation stage. Adapted from [1]. 
 
1.2.2. Early differentiation 
Keratinocytes undergo a profound signaling rewiring when they detach from the 
basement membrane and begin to differentiate. In this process they lose the 
expression of the basal markers K5 and K14, which are replaced by K1, K10 and, 
later on, by involucrin and transglutaminases [4, 11] (Figure II).  
The canonical Notch pathway is one of the major drivers of keratinocyte 
differentiation (Figure II) [21]. This pathway is mainly active in suprabasal cells and 
its upregulation leads to an expansion of the spinous layer. Conversely, the 
inactivation of Notch signaling causes impaired differentiation and aberrant 
formation of the skin barrier [10, 21].  
These stages of early keratinocyte differentiation also require p63 activity, 
showing that this transcription factor plays bivalent roles in epidermal stratification 
[22]. Additionally, other proteins such as Irf6, Ovol1, Kdf1 and AP1 also have been 
















1.2.3. Late differentiation 
Late keratinocyte differentiation in the granular layer is accompanied by the 
expression of specific markers such as filagrin, loricrin and some transglutaminases 
[4] (Figure II). Along with Notch and AP1, calcium signaling is one of the most 
prominent pathways at this stage. Such signaling is mediated by the extracellular 
calcium-sensing receptor (CaR) and the serine/threonine kinase PKCα, whose 
respective overexpression leads to expanded layers of highly differentiated 
keratinocytes [23, 24]. In addition, the transcription factors Klf4 and Grhl3 have also 















2. EPIDERMAL STEM CELLS 
2.1. NICHES AND POPULATIONS 
2.1.1. Interfollicular epidermis stem cells 
The homeostatic maintenance of the squamous epithelium relies on cells capable of 
ensuring the turnover of the tissue throughout the whole life of the organism. This 
demand requires a fine-tuned balance between quiescence and proliferation that 
allows the generation of differentiated lineages while preserving an undifferentiated 
progenitor pool. That is the function of the stem cells of the squamous epithelium, 
which reside in specific niches. As previously mentioned, the basal layer of the 
interfollicular epidermis contains cells with those properties; however, it is in the 
hair follicle where the majority of stem niches are found (Figure III). 
Figure	III	
 
FIGURE III. Stem cell populations within the epidermis. Schematic representation of the hair 
follicle and the interfollicular epidermis with the different epidermal stem cell (SC) niches, 
populations and expression markers. The structural parts of the hair follicle are also indicated. 















The basal layer of the epidermis contains fast cycling unipotent progenitors 
characterized by the expression of high levels of β1 and α6 integrins and low levels 
of the transferrin receptor (CD71) (Figure III) [26, 27]. These cells maintain a 
constant cell number within the interfollicular epidermis (IFE) by compensating the 
cells lost by desquamation. To that end, upon division they generate a daughter stem 
cell and a poised progenitor that leaves the basal layer towards the terminal 
differentiation pathway [28]. Although under physiological conditions these cells 
take care of the IFE independently of other stem populations [29, 30], it has been 
shown that upon challenges, such as wounding, stem cells from the hair follicle also 
intervene [26]. 
2.1.2. Hair follicle stem cells 
The hair follicle is a dynamic cylindrical structure composed of epidermal cells 
arranged in several concentric layers of sheath and hair-producing keratinocytes. 
This body is usually associated with accessory structures such as the sebaceous gland 
and the arector pili muscle (for a review, see [31]). In terms of structure, the hair 
follicle is divided in infundibulum, isthmus and bulb (Figure III). The infundibulum 
connects the opening of the hair canal with the isthmus through the junctional zone, 
where the insertion point of the arector pili muscle is found. The isthmus connects 
with the bulb at the bulge, the lower end of the non-cycling fraction of the hair 
follicle. The bulb contains the matrix keratinocytes, the pigmentary unit and the 
mesoderm-derived dermal papilla, all of which participate in the generation of the 
hair shaft and the surrounding epidermal layers. 
The upper part of the hair follicle is known to contain various kinds of 
unipotent stem cells that take care of homeostatic demands in an independent fashion 
[10] (Figure III). Under physiological conditions their contributions are restricted to 
the areas where they are found, i.e., Lrig1- and MTS24-positive cells at the 
junctional zone, Blimp1-positive cells at the sebaceous gland, and Lgr6-positive cells 
at the isthmus. However, these cells have the potential to give rise to all epidermal 
lineages, proving their plasticity as stem cells [32-36]. Despite this, when looking for 
quiescence as one of the key features of true stem cells, one region in the hair follicle 














Label-retention studies in the early 1990s showed that the bulge contains the 
slowest cycling stem cell population of the whole epidermis, characterized by the 
expression of CD34, K15 and high levels of integrin α6 (Figure III) [37-39]. These 
cells fuel and replenish the hair follicle matrix in order to produce the hair shaft and 
its surrounding layers [10]. In addition, they also i) participate actively in the 
epidermis repair following wounding, ii) have a long-lived clonogenic nature when 
cultured in vitro and iii) are able to fully regenerate the epidermal tissue upon 
transplantation, including all its structures and lineages [40-42]. For these 
characteristics, such pool of bulge-residing multipotent cells has been traditionally 
viewed as the main epidermal stem cell (EpSC) population. 
 
2.2. MOLECULAR REGULATION OF THE BULGE STEM CELL 
Unlike the case of the progenitors of the upper hair follicle, the activity of the EpSC 
is intimately linked to the hair follicle cycle. Hair follicles transition through rest 
(telogen), growth (anagen) and regression (catagen) phases in order to produce new 
hair, a process that is orchestrated by a highly-regulated balance between activation 
and quiescence cues within the EpSC niche (for a review see [31]) (Figure IV).  
Figure	IV	
 
FIGURE IV. The hair follicle cycle. Schematic representation of the different phases of the hair 



















During telogen, quiescence is maintained in the bulge through the presence of 
extrinsic inhibitory signals. Among these, BMP signaling is essential as it regulates 
the expression of the key CDK4-repressor Nfatc1, and the absence of Bmpr1a results 
in a continuously activated follicle [43-45]. Hence, equilibrium between BMP 
ligands (Bmp2/4/6) and antagonists (Noggin) is required for proper hair follicle 
cycling (Figure IV) [46]. Quiescence within the EpSC niche is also regulated by 
Tcf3, which represses the Wnt/β-catenin signaling pathway, and the multipotency-
associated the transcription factors Lhx2, Sox9 and c-Myc [31].  
2.2.2. Proliferation 
EpSC quiescence is maintained as long as Bmp levels are elevated, as these factors 
make the EpSC insensitive to anagen-inducing agents [47]. However, when BMP 
signaling decreases and activating cues from the dermal papilla reach certain levels, 
EpSC begin to proliferate and telogen gives way to anagen (Figure IV) [31]. One of 
the key elements regulating this transition is the Wnt/β-catenin signaling pathway, 
which also plays many other crucial roles in hair follicle morphogenesis, the 
maintenance of the EpSC identity and the promotion of terminal differentiation [48]. 
Consistent with this, the deletion of β-catenin results in either absent or aberrant hair 
follicle formation and the generation of epidermal cysts [49]. Conversely, its 
overexpression induces EpSC proliferation and anagen reentry [49].  
Downstream of Wnt/β-catenin, Shh signaling is another crucial component in 
EpSC activation. The blockade of this pathway prevents the expansion of hair 
follicle progenitors and impairs anagen progression, while its activation leads to a 
rise in the number of hair follicles in anagen [50, 51]. Other transcription factors 
such as c-Myc and Runx1 also become upregulated upon EpSC activation [31].  
Once activated, the proliferation of EpSC induces the growth of the lower 
fraction of the hair follicle, thus moving the bulge away from the dermal papilla and 
eventually making the EpSC go back to quiescence. At the same time, the EpSC-
derived transient-amplifying cells at the hair matrix in the bulb continue dividing 
until they differentiate towards the various epithelial lineages [31] (Figure IV).  
2.2.3. Regression 
Along with a series of catagen-inducing soluble factors that include Fgf5, Tgfb1, Il-
1β, Bmp2/4 and Tnf-α, the receptors for the vitamin D and the retinoic acid seem to 














When catagen is established, the destructive phase starts and apoptosis of 
matrix and sheath keratinocytes leads to the regression of the lower two-thirds of the 
hair follicle. As a result, the bulge and the dermal papilla are brought close together 
















3. THE SQUAMOUS CELL CARCINOMA 
3.1. EPIDEMIOLOGY 
The squamous cell carcinoma (SCC) results from the accumulation of oncogenic 
events in any squamous epithelium of the human body, which as a whole makes it 
the most common cancer worldwide [54, 55]. The majority of the cases belong to 
one of the four main subgroups: cutaneous SCC (cSCC), head and neck SCC 
(hnSCC), esophageal SCC (eSCC) and lung SCC (lSCC). Among these, two arise 
from keratinized epithelia: the cSCC and hnSCC (Figure V). 
Figure	V	
 
FIGURE V. Epidemiology of cSCC and hnSCC. Scheme indicating the most relevant 
epidemiological parameters associated with cSCC and hnSCC. Histological images where obtained 
from the HSP atlas. 
 
3.1.1. Cutaneous squamous cell carcinoma 
The cSCC is the second most common nonmelanoma skin cancer, representing from 
20% to 50% of all cases [56], an incidence rate that is currently climbing [57]. The 














radiation exposure, which along with other non-behavioral factors such as age and 
skin color is the key contributor to cSCC development (Figure V) [56, 57]. 
Fortunately, the majority of these tumors can be successfully eradicated by surgery, 
which translates to 5-year mortality rates below 5% [56, 57]. Nevertheless, this 
cancer still accounts for 20% of all skin cancer-related deaths and constitutes a 
serious burden for our health systems given its extremely high incidence [54]. 
Furthermore, around 5% of cSCC cases display very aggressive features, with high 
recurrence, elevated metastatic potential, and poor response to the available 
therapeutic options [55, 57]. 
3.1.2. Head and neck squamous cell carcinoma 
The hnSCC can arise from the nasal and oral cavities, the pharynx and the larynx. It 
is the sixth most common type of cancer worldwide, and makes up more than 90% of 
all head and neck tumors (Figure V) [55, 58]. Over the past decade there has been a 
notorious change in the incidence of the different hnSCC subtypes, with a decline in 
larynx and hypopharynx cases and a concomitant increase in oral SCC tumors [55, 
59]. For these cancers, the main risk factors are alcohol and tobacco consumption, 
both separately and in a synergistic manner. In addition, human papillomavirus 
(HPV) infection is associated with 25-45% of all hnSCC tumors, which tend to be 
less aggressive than the HPV-negative counterparts [55]. Given its body location the 
hnSCC is usually detected in advanced stages, which leads to a 5-year mortality rate 
of 40-50% [60]. 
The oral SCC (oSCC) is a subtype of hnSCC that arises from the tongue, the 
floor of mouth, the buccal and alveolar surfaces and the hard palate. This is the 
hnSCC subtype that constitutes the greatest threat, as its incidence is currently 
climbing in young individuals who are not exposed to the traditional risk factors 
[61]. The most common oSCC subtype is the tongue SCC, which also has one of 
worst prognosis [58, 61]. 
 
3.2. CELL OF ORIGIN 
Given the high cell turnover rate that characterizes squamous epithelia, it would 
seem prima facie that the only oncogenic events that can give rise to the development 














demonstrated by the classic chemically-induced SCC mouse carcinogenesis model, 
which is based on a single topical treatment with the carcinogen DMBA (7,12-
dimethylbenz[a]anthracene) followed by periodic applications of the proliferation-
inducing agent TPA (12-O-tetradecanoylphorbol-13-acetate) [62]. Since TPA can 
induce the formation of papillomas even one year after DMBA treatment, the 
DMBA-induced mutations necessarily need to occur in long-lived epidermal cells 
[63, 64].  
These long-lived cells include both the progenitors at the basal layers of the 
epithelium and, in the case of the epidermis, the hair follicle stem cells. This is 
corroborated by the fact that mice with either of those two cell compartments 
disrupted develop a reduced number of tumors upon chemical carcinogenesis [65]. 
Furthermore, it has been proved that the expression of oncogenic KRas along with 
p53 deletion in the interfollicular epidermis, the hair follicle lineages, or the oral 
basal cells, results in the development of SCC [66-68].  
Interestingly, although the aforementioned studies demonstrate that the stem 
cell compartment is the primary niche where carcinogenesis occurs, several studies 
have revealed that transit-amplifying cells and post-mitotic keratinocytes can also 
give rise to tumors, although of reduced malignancy. For example, differentiated 
suprabasal cells from the interfollicular epidermis can also lead to neoplastic changes 
and tumor formation when the expression of an oncogene, such as HRas or c-Myc, is 
induced [65, 69-71]. 
 
3.3. MOLECULAR FEATURES 
In order to elucidate the molecular players that drive SCC carcinogenesis, extensive 
molecular profiling of tumors collected from a large number of patients has been 
performed in the last years. Such analyses have revealed that despite their separate 
body location and their diverse risk factors, the different SCC subtypes share a 
remarkably conserved molecular signature in terms of mutation, copy-number 
variation, methylation, mRNA expression, microRNA expression and, in some cases, 
protein expression [72, 73]. This conserved SCC signature is dominated by genes 
associated with cell cycle control, response to growth factors, Ras/MAPK signaling, 
















FIGURE VI. Common genetic lesions in cSCC and hnSCC. Functionally-arranged wordclouds 
representing the targets of the most frequent mutations and copy number variations found in cSCC 
and hnSCC. The size of the gene name is proportional to the genetic lesion frequency [54]. 
 
3.3.1. Cell cycle control 
In terms of cell cycle control, the tumor suppressors TP53 and CDKN2A are the most 
frequently mutated genes in every HPV-negative SCC subtype (Figure VI) [54, 60]. 
Alternatively, in HPV-positive tumors the viral proteins E6 and E7 inhibit P53 and 
RB proteins directly [54, 60]. This loss of key players in cell cycle arrest is 
frequently accompanied by amplifications of proliferation-driving genes, especially 
CCND1 and MYC [54, 60]. Along with them, the ubiquitin ligase FBXW7, which is 
involved in the degradation of cell-cycle regulatory molecules such as cyclin E and 
c-MYC, is also highly mutated in SCC [54, 60]. The conjunction of these genomic 
lesions promotes an accelerated cell cycle deprived of checkpoint mechanisms, 
leading to the appearance of further oncogenic lesions.  
3.3.2. Signal transduction 
Mutations in some tyrosine kinase receptors (TKR) involved in growth factor 














most prominent case, as it is commonly amplified [54, 60]. To a lesser extent, the 
genes encoding C-MET, FGFR1, FGFR2 and FGFR3 are also recurrently amplified 
[54, 60]. The signals from these tyrosine kinases are integrated by the downstream 
RAS/MAPK and PI3K signaling pathways. At this level, HRAS mutations are 
frequently found in cSCC and HPV-negative hnSCC, whereas KRAS and NRAS 
mutations are detected at lower frequencies [54, 74]. The PI3K/AKT pathway is 
frequently altered through the amplification or mutation of PIK3CA or, alternatively, 
through the loss of PTEN [54, 72]. The deregulation of the TKR-RAS/MAPK/PI3K 
signaling axes leads to an increase in both the proliferation and survival potential of 
the SCC cell. 
The Wnt signaling pathway is another preferred target in SCC tumors 
(Figure VI). This is probably owing to the role of Wnt in stem cell maintenance and 
carcinogenesis [60]. Such role is mainly mediated by β-catenin, which explains why 
the cadherin-related FAT1 protein, that sequesters β-catenin at the plasma 
membrane, is so frequently mutated in SCC [75]. Another member of the pathway 
recurrently mutated, the LIM domain-containing protein AJUBA, is also involved in 
the control of β-catenin, in this case through the activation of GSK3β-mediated 
degradation [76]. Interestingly, these two proteins are also connected to the Hippo 
signaling pathway [77], whose downstream regulators YAP and TAZ are known 
players in SCC development [78]. 
3.3.3. Squamous differentiation and specificaction 
Among the genes involved in squamous specification, the transcription factor TP63 
is frequently overexpressed, but rarely mutated, in SCC (Figure VI) [54]. Also 
recurrently amplified is SOX2, a key mediator of pluripotency and squamous 
epithelium embryogenesis which is known to physically interact with P63 [79, 80]. 
On the other hand, and in keeping with its role in the promotion of keratinocyte 
differentiation, NOTCH1 is commonly found either downmodulated or with loss-of-
function mutations in virtually every SCC subtype [54]. To a lesser extent, this also 
occurs in the cases of NOTCH2 and NOTCH3 [54]. 
3.3.4. Epigenetics 
Some epigenetic regulators involved in the control of processes such as proliferation 














includes the mutation of the N-methyltransferases NSD1, KMT2C, KMT2D, EZH2 
and the acetyltransferase EP300 [54, 60]. In addition, some microRNAs have been 
described to be consistently downmodulated in SCC, such as miR-let-7c-5p and 
miR-100-5p [60]. 
3.3.5. RHO signaling 
Functional analyses of these molecular features indicate that SCC cells are highly 
dependent on signaling pathways involved in proliferation, differentiation, MAPK 
signal transduction, hypoxia-related responses, and motility processes [72, 73]. 
Recently, pan-cancer multiomic analyses revealed that such molecular signature is 
linked to a SCC-specific enrichment of RAC and RHO signaling output [72]. This 
drew our interest, as although the roles of RHO GTPases in cell biology have been 
extensively characterized in vitro, their true relevance in vivo remains obscure, both 
in physiological and pathological scenarios. For this reason, we made RHO signaling 















4. RHO SIGNALING IN SQUAMOUS EPITHELIA 
4.1. RHO GTPASES AS MOLECULAR SWITCHES 
4.1.1. The family of Rho GTPases 
Rho GTPases are small G proteins that respond to extracellular cues to regulate a 
variety of cellular processes including cytoskeletal dynamics, polarity, migration, 
proliferation, differentiation and survival [81, 82]. These proteins make up a large 
family which is classified into the Rho (RhoA, RhoB, RhoC), Rac (Rac1, Rac2, 
Rac3, RhoG), Cdc42 (Cdc42, RhoQ, RhoJ), RhoD (RhoD, RhoF), RhoH, RhoU 
(RhoU, RhoV) and Rnd (Rnd1, Rnd2, Rnd3) subfamilies [83]. Among these, RhoA, 
Rac1 and Cdc42 are the best-characterized GTPases in terms of biochemical 
properties, molecular regulation and biological roles. 
Most Rho GTPases cycle between two conformations according to the 
guanosine molecule residing at their nucleotide-binding pocket: an inactive one in 
the presence of GDP and an active counterpart in presence of GTP. Hence, the 
activation of these proteins takes place when the GDP molecule is exchanged for 
GTP, a process that requires the catalytic activity of a family of proteins known as 
guanine nucleotide exchange factors (GEFs). On the other hand, the GTP-to-GDP 
hydrolysis abrogates the activity of the GTPases and is catalyzed by GTPase 
activating proteins (GAPs). In this inactive state, guanine nucleotide dissociation 
inhibitors (GDIs) can bind to and sequester Rho GTPases in order to prevent their 
activation [81, 82]. All together, GEFs, GAPs and GDIs are the key players that 
make Rho GTPases function as molecular switches, thus enabling them to 
dynamically integrate and transduce the different extracellular signals into the 
appropriate cellular responses (Figure VII). Such signal transduction is mediated by 
a set of proximal effectors that interact with the GTP-bound form of the GTPases. 
Over 60 Rho GTPase proximal effectors have been characterized so far, which 
include: i) regulators of the cytoskeleton, ii) transcription factors, iii) serine/threonine 
kinases, iv) tyrosine kinases, and v) phospholipid kinases, among others [83]. Each 
GTPase binds to a particular collection of effectors, which is one of the key 
















FIGURE VII. Rho GTPases function as molecular switches. Scheme depicting the main agents 
and mechanisms that regulate the activity of Rho GTPases. 
 
4.1.2. The family of Rho exchange factors 
The Rho GEFs constitute a large and heterogeneous family of more than 70 members 
that differ in expression patterns, subcellular locations, regulatory mechanisms, Rho 
GTPase specificity, scaffolding of downstream effectors and other non-catalytical 
functions (Figure VIII). Such diversity is linked to their structure: a GEF-specific 
set of domains that accompanies a conserved Dbl or Dock catalytic core (for a 
review, see [85]).  
In the activation of Rho GTPases, Rho GEFs play a doubly-essential role as 
they catalyze the GDP-for-GTP exchange and also function as scaffolds that bring 
GTPase and effector into close proximity. Consequently, one of the best-
characterized mechanisms of Rho GTPase hyperactivation is through the 
upregulation of GEF activity, either by mutation or increased expression [83, 85, 86]. 
This shows that GEFs can be very relevant in the pathobiological programs mediated 
by Rho GTPases, and even have potential therapeutic value for some Rho-signaling-














role of these proteins in physiologically- and pathologically-relevant contexts still 
remains poorly characterized.  
Figure	VIII	
 
FIGURE VIII. Rho GEFs constitute a large and heterogeneous family. Dendrogram showing the 
phylogenetic classification and the catalytic specificity of every Rho GEF. Adapted from [85]. 
 
4.2. RHO GTPASES IN EPIDERMAL STEM CELL 
HOMEOSTASIS 
Discovered on the basis of their homology to Ras GTPases, most studies on Rho 
GTPases have been primarily directed towards tumorigenesis-related processes. This 














maintenance of tissue homeostasis in purely physiological settings. However, their 
well-documented roles in adhesion, proliferation and differentiation suggest that Rho 
GTPases play crucial roles in the maintenance of many tissues, including the 
epidermis. Supporting this hypothesis, some mouse models have shown that 
epidermal stem cells are strongly dependent on Rho signaling. 
Rac1 has been found by several studies to be unequivocally essential for the 
maintenance of the EpSC population [87-89]. Different knockout mice for this 
GTPase display a dramatic differentiation and exhaustion of the EpSC reservoir at 
the hair follicle bulge, which translates to defective hair follicle formation [87-89]. 
Furthermore, depletion of epidermal Rac1 also leads to loss of clonogenic potential 
[87, 90] and impaired wound healing, both in vivo and in vitro [89, 91]. Whether the 
deletion of Rac1 also affects the integrity of the interfollicular epidermis, however, 
has been the subject of conflicting reports. Although it was initially proposed that 
this GTPase would be essential for the maintenance of the epidermis, later studies 
found that Rac1 is dispensable in such context [87-89]. 
Much less is known of the role of RhoA in epidermal stem cell homeostasis, 
as its depletion does not lead to overt epidermal defects [92]. Nevertheless, in vitro 
studies have shown that this GTPase regulates EpSC proliferation, migration and 
differentiation [93-95]. There are also evidences associating Cdc42 signaling with 
the fitness of epidermal stem cells, as it has been shown in vivo that this GTPase 
regulates the fate of hair follicle progenitor cells through the control of β-catenin 
turnover [96].  
These findings demonstrate that balanced Rho signaling is required for the 
homeostasis of epidermal stem cells, but also underscore how little is currently 
known of the mechanisms and agents that physiologically mediate such balance. In 
this regard, a number of indirect evidences coming from both in silico and in vivo 
models suggest that Rho GEFs might play an instrumental role [95, 97, 98]. 
 
4.3. RHO GTPASES IN SQUAMOUS CELL CARCINOMA 
The first evidences pointing towards an implication of Rho GTPases in cancer cell 
growth came from the transforming activity that some of them displayed in vitro 














GTPases were key regulators of cancer-associated processes [81, 82]. However, the 
assumption that these proteins were actually relevant for human cancer was for a 
long time challenged by the fact that, unlike RAS proteins, mutations in RHO 
GTPases were rarely found in human cancers. It was not until the recent 
development of Next Generation Sequencing technologies and the conduction of 
large high-throughput genomic and transcriptomic studies of human tumors that this 
paradigm shifted [83]. Currently, both human- and mouse-derived data demonstrate 
that Rho GTPases play crucial roles in various cancer types, including cSCC and 
hnSCC (Figure IX). 
Figure	IX	
 
FIGURE IX. Implication of Rho GTPases in SCC. Scheme summarizing the current human- and 
mouse-based evidences of the involvement of Rho GTPases in cSCC and hnSCC carcinogenesis. 
Putative pro- and anti-tumorigenic implications are highlighted in red and blue, respectively. 
 
4.3.1. Rac family in SCC carcinogenesis 
Among the Rho family, Rac1 is the most unequivocally SCC-associated member 
(Figure IX). This GTPase is recurrently found upregulated in cSCC and hnSCC, 
where its GTP-bound levels are also elevated [86, 87, 100, 101]. In addition, RAC1 
is the RHO GTPase with the highest frequency of mutation in these tumors [83, 86]. 
These mutations frequently target the P29 residue and turn RAC1 into a hyperactive 














Such tumor-derived evidences suggest that RAC1 plays a protumorigenic role 
in SCC. In line with this, Rac1 deletion in mouse models confers protection from 
DMBA+TPA-induced skin tumors and K-RasG12D-induced oral tumors [102, 103]. 
The loss of Rac1 downstream effectors such as Pak1 also abrogates the development 
of tumors in these carcinogenic models, further demonstrating the implication of the 
Rac1 signaling axis in SCC carcinogenesis [104, 105]. 
4.3.2. Rho family in SCC carcinogenesis 
Rho subfamily members seem to play both pro- and anti-tumorigenic roles in 
different biological settings (Figure IX). Although many of them are yet to be 
characterized, most RHOA mutations found in hnSCC seem to induce a loss of 
function of the protein [83, 106]. In line with this, loss of RhoA in mouse models of 
DMBA+TPA-induced skin tumors translates to an increased tumor multiplicity, an 
indication that this GTPase functions as a tumor suppressor in SCC development [86, 
107]. Nevertheless, both RHOA and RHOC have been found upregulated in 
squamous cell carcinomas, where they have been associated with poor prognosis 
[108]. This suggests that RHOA might also play prooncogenic functions in some 
context of SCC development. Consistent with the latter possibility, the activation of 
the RhoA downstream effector Rock2 results in an increased development of skin 
tumors in DMBA+TPA- and HRasG12V-based SCC mouse models [83, 109].  
Similarly puzzling observations are made in the case of RHOB. Although it is 
rarely mutated, reduced expression of RHOB is observed in hnSCC [86], which 
would suggest that this GTPase plays anti-tumorigenic roles. However, mouse 
models studies suggest that the picture is more complex, as loss of RhoB enhances 
and abrogates skin SCC tumorigenesis induced by DMBA+TPA and ultraviolet 
radiation, respectively [110, 111].  
4.3.3. Cdc42 family in SCC carcinogenesis 
Among the three main RHO GTPases, CDC42 seems to be the least relevant for SCC 
carcinogenesis. Very few mutations or transcriptional alterations have been detected 
in this gene so far, and the ones found are yet to be functionally characterized. Up to 
now, it has been implicated in other tumors such as melanoma, breast, lung and 















4.4. RHO GEFS IN SQUAMOUS CELL CARCINOMA 
The pivotal role of Rac and Rho GTPases in SCC carcinogesis makes them 
appealing targets for anti-cancer therapeutics. However, GTPases are poorly 
druggable proteins, so their function cannot be pharmacologically blocked directly 
[100]. For this reason, the identification of the mediators that regulate the activity of 
these proteins in the carcinogenic context might provide valuable tools to harness 
Rho activity towards potential novel therapeutic avenues. 
Since the activation of Rho GTPases relies on Rho GEFs, it is reasonable to 
hypothesize that the latter might be responsible for some of the Rho signaling 
deregulation events that occur in cancer. Nevertheless, experimentally-validated 
roles associated to SCC carcinogenesis have only been found for a reduced number 
of GEFs, namely, Ect2, Tiam1 and some members of the Vav family. 
4.4.1. Ect2 
Ect2 is a nuclear exchange factor for Rac, Rho and Cdc42 GTPases with a key role 
in cytokinesis and rRNA synthesis [106, 112, 113]. This GEF is a well-established 
oncogene that is found upregulated in a high number of cancers, including hnSCC 
[85, 106, 114]. Such upregulation is, at least in some tumors, accompanied by the 
mislocalization of the protein, which migrates from the nucleus to the cytoplasm 
where it promotes ectopic Rac activation [85, 106, 114]. Despite these preliminary 
evidences, the actual role that this GEF might play in SCC carcinogenesis is not 
known as currently there are no mouse-model-based studies. 
4.4.2. Tiam1 
Tiam1 is a Rac-specific GEF that was initially identified due to its relevance in T-
cell lymphoma invasion [115]. Years later, HRas-driven mouse models of skin 
cancer showed that this GEF is also relevant for SCC tumorigenesis. Upon 
DMBA+TPA treatment, Tiam1-deficient mice develop fewer tumors, of smaller size 
and with longer latency than the wild-type counterparts [98] (Figure X). However, 
the tumors that eventually develop in this model display an exacerbated malignancy. 
These results suggest that in some biological scenarios this GEF might conceal an 
anti-tumorigenic role. Consistent with this notion, TIAM1 levels decrease with the 
















FIGURE X. Tiam1 and Vav GEFs play crucial roles in SCC development. Scheme summarizing 
the findings derived from the two only mouse models that so far have been used to assess the 
relevance of Rho GEFs in SCC development [97, 98]. Putative pro- and anti-tumorigenic implications 
are highlighted in red and blue, respectively. 
 
4.4.3. Vav family 
Vav proteins are tyrosine-phosphorylation-regulated GEFs that catalyze the 
activation of Rac1 and RhoA GTPases. Despite their similarity, the three members of 
the family are characterized by fairly divergent spectra of physiopathological roles 
(for a review, see [117]).  
Vav2 and Vav3 display a ubiquitous expression pattern and play key 
homeostatic functions in a number of tissues, including the cardiovascular system 
and the brainstem, respectively [117-122]. Although these GEFs have been 
associated to a number of solid tumors [123-127], the only findings currently 
validated by mouse models are circumscribed to skin and breast cancer [97, 128]. 
Since traditionally these two GEFs have been deemed to play partially overlapping 
functions, such studies have been performed in a Vav2–/–;Vav3–/– double knockout 
mouse model. These animals allowed to discover that Vav2 and Vav3 cooperate in 
the epidermal compartment to control an autocrine and paracrine program linked to 
proliferation and the creation of a proinflamatory environment that impinges on 














carcinogenesis, Vav2–/–;Vav3–/– mice develop fewer, smaller and more benign tumors 
than the wild-type couterparts [97] (Figure X). 
Unlike Vav2 and Vav3, the first member of the Vav family is not thought to 
participate in SCC carcinogenesis, as it is primarily expressed in hematopoietic cells. 
In this cell compartment Vav1 plays essential roles in lymphocyte development and 
tumorigenesis [117, 129, 130]. It should be noted, however, that ectopic expression 
of VAV1 has been detected in some solid tumors [131-133], and thus a potential 
contribution of this GEF to SCC tumors cannot be entirely ruled out.  
 
4.5. DO RHO GEFS HARBOR THERAPEUTIC VALUE? 
Although the aforementioned studies provide valuable data demonstrating that some 
Rho GEFs can play relevant roles in SCC carcinogenesis, the lack of appropriate 
models leaves unanswered some of the most fundamental questions so as to exploit 
this knowledge in a biomedical scenario. Can the gain of function of a single GEF 
promote SCC? Are the results obtained from mouse models valid for human tumors? 
Are GEFs approachable as therapeutic targets? How would such therapy interfere 
with their physiological roles? 
In order to address these questions, focusing on Rac1 GEFs seems prima 
facie the most promising approach. This is due to the fact that, as mentioned before: 
i) Rac1 is the only Rho GTPase to unequivocally play a protumorigenic role in SCC, 
ii) the activity of this GTPase is consistently increased in SCC tumors, iii) the 
mutation frequency in the RAC1 gene cannot account for such increased activity and 
iv) the abrogation of Rac1 signaling abrogates SCC development in mouse models. 
Interestingly, previous reports suggest that this increase in RAC1 activity in SCC 
cells is mediated, at least in part, by the GEF VAV2 [124]. Such observation is in 
keeping with the fact that Vav2–/–;Vav3–/– mice are resistant to SCC development in 
skin carcinogenesis models [97]. For these reasons, we thought Vav2 would be an 
ideal candidate to investigate the significance and exploitability of Rho GEF 































Based on the preceding evidence, the research presented in this Ph.D. thesis pursues 
the following main objectives: 
  
1. To characterize the implication and role of the Rho GEF Vav2 in the 
carcinogenesis of cutaneous and head–and–neck squamous cell carcinomas. 
 
2. To evaluate the therapeutic value of the inhibition of Vav2 catalytic activity 
in squamous cell carcinoma. 
 
3. To investigate the physiological roles of Vav2 associated to the homeostatic 
maintenance of the squamous epithelium. 
 
4. To identify and validate additional Rho exchange factors with relevant 



























EXPERIMENTAL MODEL AND SUBJECT DETAILS 
Ethics statement 
Animal work was done according to protocols approved by the Bioethics committee 
of Salamanca University. The use of patient samples was done according to methods 
and informed patient consent policies approved by the Bioethics committees of both 
the Institute for Research in Biomedicine and Vall d’Hebron Research Institute. 
Mouse experiments 
Vav2Onc, Vav2–/–, Vav3–/–, Vav2–/–;Vav3–/–, and Vav1–/–;Vav2–/–;Vav3–/– mice have 
been described elsewhere [97, 122, 134, 135]. The Vav2L332A knock–in mouse strain 
was generated by GenOway using the indicated vector in Figure 8.1 following 
standard homologous recombination techniques in embryonic stem cells.  
For carcinogenesis experiments in newborn mice, 3–day–old mice received a 
single application of 5 µg of DMBA (Sigma, Catalog No. D3254) in 200 µl of 
acetone. For complete carcinogenesis experiments in adult mice, the backs of 6– to 
8–week–old animals of the indicated genotypes were shaved and treated biweekly 
with 5 µg of DMBA in 200 µl of acetone for 20 weeks. The two–step carcinogenic 
DMBA/TPA protocol was initiated with a single topic application of 200 µl of 
0.013% DMBA dissolved as above followed by biweekly applications of 200 µl of 
1×10−4 M TPA (Sigma, Catalog No. P8139) dissolved in acetone for the indicated 
period of time. The number, size and incidence of tumors were monitored weekly. 
Time–course studies of the in vivo response of the epithelia of WT and Vav2Onc mice 
to TPA using both determination of epithelial hyperplasia and BrdU incorporation 
were carried out as indicated before [97]. Upon euthanasia, tumors and tissue 
samples were collected and processed for both histological and 
immunohistochemical analyses. 
For the tongue orthotopic xenograft experiments, exponentially growing 
oSCC patient derived cells were detached using accutase (CELLnTEC, Catalog No. 
CnT–Accutase–100), centrifuged at 300 xg for 5 min, and resuspended in culture 
medium at a density of 1.7 x 106 cells per ml. 5 x 104 SCC cells were then introduced 










tongues of 6– to 8–week–old Vav1–/–;Vav2–/–;Vav3–/– mice previously anesthetized 
by injecting intraperitoneally 200 µl of a mixture of 10 mg/ml ketamine (Merial, 
Catalog No. Imalgene 1000) and 2 mg/ml xylazine (Bayer, Catalog No. Rompun) in 
phosphate buffered saline solution. Growth of tumors was then periodically 
visualized using an IVIS Lumina In Vivo Imaging System (PerkinElmer, Catalog 
No. CLS136334) upon administering 50 µl of a 5 mg/ml solution of D–luciferine 
(Goldbio, Catalog No. LUCK–500) to mice. This procedure was performed with 
animals anesthetized as above. Mice were reanimated after finishing the recordings 
by injecting intraperitoneally 200 µl of a 1 mg/ml atipamezole (Ecuphar, Catalog No. 
Antisedan) solution in phosphate buffered saline solution. Upon euthanasia, tumors 
were collected and processed for pathological and immunohistochemical analyses. 
Cardiovascular and renal parameters were determined as previously described 
in 4-month-old male mice [118]. 
Wound healing assays were performed in 8/10-week-old mice using a scalpel 
(Swann-Morton, Catalog No. 0508) or a biopsy punch (Stiefel, Catalog No. BI1500). 
Two days after shaving, a 1-cm incision was made in the dorsal skin and its healing 
was monitored daily. For hair regeneration assays, 8/10-week-old mice were shaved 
and hair growth was followed up daily.  
For label-retaining cell (LRC) pulse-chase experiments, 50 mg/kg of BrdU 
(5-bromo-2’-deoxyuridine) (ThermoFisher, Catalog No. B23151) were injected 
intraperitoneally in 10-day-old mice every 12 hours for a total of 4 injections and 
chased after 80 days. For epidermal cell proliferation assays, 1 mg of BrdU (5-
bromo-2’-deoxyuridine) (ThermoFisher, Catalog No. B23151) or EdU (5-ethynyl-2’-
deoxyuridine) (Invitrogen, Catalog No. A10044) was injected intraperitoneally 1 
hour before euthanasia in mice of the indicated ages.  
For skin stimulation experiments, the dorsal skin of shaved animals was 
treated with 200 µL of an acetone solution of 3.3x10–5 M TPA (12-O-tetradecanoyl-
phorbol-13-acetate) (Sigma, Catalog No. P8139). Mice were euthanized 24 hours 
later. 
For skin xenograft experiments, keratinocytes and fibroblasts were isolated 
from donor mice as indicated previously [97]. Briefly, the skin from newborn mice 










with 5 mg/mL of dispase (Roche, Catalog No. 04942078001) overnight at 4ºC to 
separate the epidermis from the dermis. For keratinocyte isolation, the epidermis was 
then incubated with accutase (CELLnTEC, Catalog No. CnT-Accutase-100) for 30 
minutes at 37ºC. For fibroblast isolation, the dermis was digested in DMEM 
(ThermoFisher, Catalog No. 11995065) with 0.25% collagenase (Sigma, Catalog No. 
C5138) for 1 hour at room temperature. All the keratinocytes resulting from one 
newborn mouse plus 4 x106 dermal cells were combined in a cell suspension for each 
xenograft. 8-week-old nude mice (Charles River, Catalog No. NU/NU) were 
anesthesized with 100 µL of a mixture of 25 mg/mL ketamine (Merial, Catalog No. 
Imalgene 1000), 2 mg/mL diazepam (Roche, Catalog No. Valium) and 0.1 mg/mL 
atropine (Braun, Catalog No. Atropine B) and placed on a heating pad. After 
cleaning the dorsal surface with iodopovidone, a 1-cm incision in the skin was made 
to insert a skin xenograft chamber as reported before [136]. The chamber was then 
secured with stitches and the cell suspension was introduced. One week after the 
intervention, mice were anesthesized and the chamber was removed. Six weeks later, 
skin reconstitution was considered completed and animals were injected 
intraperitoneally with 50 mg/kg of BrdU and sacrificed 1 hour later. Xenografted 
skin was taken for histological studies (see below). [130] 
Primary mouse keratinocytes 
Primary keratinocytes were isolated as described elsewhere [97]. Briefly, the skin 
from newborn mice of the indicated genotypes was treated with 250 U/ml of dispase 
(Roche, Catalog No. 04942078001) overnight at 4 °C. Next day, the epidermis was 
separated from the dermis and treated with accutase for 30 min at 37 ºC to extract the 
keratinocytes. Cultures were maintained in CnT07 medium (CELLnTEC, Catalog 
No. CnT–07) on type I collagen–precoated plates (BD Biosciences, Catalog No. 
356400). 
Commercially–available cell lines 
Immortalized, primary neonatal human keratinocytes (KerCT cells) were purchased 
from the American Type Culture Collection (Catalog No. CRL–4048) and cultured 
in KGM–Gold medium (Lonza, Catalog No. 00192060). These cells have been 










obtained from S.A.B. and cultured in KSFM medium (Thermo Fisher, Catalog No. 
17005–042) supplemented with 25 µg/ml bovine pituitary extract (Thermo Fisher, 
Catalog No. 17005–042) and 0.5 ng/ml human epidermal growth factor (Thermo 
Fisher, Catalog No. 17005–042). COS1 cells were obtained from the American Type 
Culture Collection and grown in DMEM supplemented with 10% fetal calf serum, 
1% L–glutamine, penicillin (10 µg/ml) and streptomycin (100 µg/ml). Unless 
otherwise indicated, all tissue culture reagents were obtained from Gibco. 
oSCC patient–derived cells 
These cells were obtained by S.A.B and described elsewhere [137]. VdH15 cells 
were cultured in KSFM medium supplemented with 25 µg/ml bovine pituitary 
extract and 0.5 ng/ml human epidermal growth factor. VdH01 and VdH02 cells were 
cultured in FAD+ medium that is composed of three parts of DMEM (Gibco, Catalog 
No. 21969) and one part of Ham’s F12 medium (Thermo Fisher, Catalog 
No.11765054) supplemented with 10% fetal bovine serum (Gibco, Catalog No. 
10270106), 1.8 x 10–4 M adenine (Sigma, Catalog No. A2786–5G), 0.5 µg/ml 
hydrocortisone (Sigma, Catalog No. H4001–1G), 5 µg/ml insulin (Thermo Fisher, 
Catalog No. 12585014), 10 ng/ml EGF (PreproTech, Catalog No. AF–100–15), 10–10 
M cholera toxin (Sigma, Catalog No. C8052–5MG), and 2 mM L–glutamine (Gibco, 





To generate the lentiviral vector encoding HA–tagged Vav2Onc (pCCM34), a cDNA 
fragment encoding the HA–tagged version of Vav2 (fragment 187–868) was 
amplified by PCR using the primers 5’–AAT AAC TAG TGC CAC CAT GTA CCC 
ATA CGA CGT CCC AGA CTA CGC TAA AAT GGG AAT GAC TGA GGA 
CGA C–3’ and 5’–ATA GAC CGC GGC CGC TCA CTG GAT GCC CTC CTC 
TTC TAC GTA–3’ (restriction sites underlined) and the pCMV–Vav2–HA vector as 










into the linearized pLVX–IRES–Hyg vector (Clontech, Catalog No. 632185). To 
generate the vector encoding HA–Vav2Onc+E200A (pFLM12), the pCCM34 vector was 
subjected to site–directed mutagenesis using the primers 5’–GAC AAG AGA AGC 
TGC TGC TTG TTA GCG ATT CAG GAG ACC GAG GCC AAG TAC–3’ and 
5’–CAT GAA CCG GAG CCA GAG GAC TTA GCG ATT GTT CGT CGT CGA 
AGA GAA CAG–3’ (changes used to generate the mutated codon are underlined). 
The pMIEG3, pMIEG3–Rac1F28L, pMIEG3–RhoAF30L and pMIEG3–Cdc42F28L 
plasmids have been reported before [139]. To generate the plasmid encoding EGFP–
Vav2Onc (pNM115), the plasmid pKES19 [140] was digested with BstXI, filled–in, 
and cloned into the SmaI–linearized pEGFP–C2 vector (Clontech, Catalog No. 
632481). The plasmid encoding EGFP–Vav2Onc+E200A (pFLM07) was obtained by 
site–directed mutagenesis of pNM115 using the primers 5’–GAC AAG AGA AGC 
TGC TGC TTG TTA GCG ATT CAG GAG ACC GAG GCC AAG TAC–3’ and 
5’–CAT GAA CCG GAG CCA GAG GAC TTA GCG ATT GTT CGT CGT CGA 
AGA GAA CAG–3’ (the altered nucleotides used to create the E200A mutation are 
underlined). The plasmid encoding EGFP–Vav2L332A (pSAF3) was obtained by site–
directed mutagenesis of a homemade EGFP–Vav2–encoding vector (pAA7) [141] 
using the primers 5’–GGT GCC CAT GCA ACG GGT GGC GAA GTA CCA CCT 
GCT GCT C–3’ and 5’–GAG CAG CAG GTG GTA CTT CGC CAC CCG TTG 
CAT GGG CAC C–3’ (the altered nucleotides used to create the L332A mutation are 
underlined). The plasmid encoding EGFP–Vav2del309–339 (pSAF2) was generated by 
SacI–flanked PCR amplification of the first 1285 bp (amino acids 1–308) of Vav2 
cDNA using the plasmid pAA7 as template and the primers 5’–CCG GGC GAG 
CTC AAT GGA GCA GTG GCG GCA ATG CGG C–3’ and 5’–CCG GGC GAG 
CTC TGT GCA CTC CTC CAC TTT CTG–3’ (restriction sites underlined). Upon 
SacI digestion, the cDNA fragment was cloned into the linearized pNM115 vector 
containing Vav2 sequence from nucleotide 1378 to end (amino acids 340–868). The 
plasmid encoding EGFP–Vav2Onc+L332A (pSAF1) was obtained by site–directed 
mutagenesis of pNM115 using the primers indicated for pSAF3. The plasmid 
encoding EGFP–Vav2Onc+Δ309–339 (pSAF4) was generated as indicated for pSAF2 
using the plasmid pNM115 as template and the primers 5’–CCG GGC GAG CTC 
AAT GGG CAT GAC TGA GGA CGA CAA G–3’ and 5’–CCG GGC GAG CTC 
TGT GCA CTC CTC CAC TTT CTG–3’ (restriction sites underlined). Plasmids 










provided by P.M. Fernández–Salguero (Department of Biochemistry and Molecular 
Biology, Extremadura University, Badajoz, Spain). 
The luciferase plasmids used to assay promoter activation included: pAP1–
Luc (AP1 reporter, obtained from Stratagene), pBV–Myc–Del1–Luc (c–Myc 
reporter, obtained from Addgene, Catalog No. 16601), pGL2–Chk1–WT–Luc (E2F 
reporter, obtained from A.M. Zubiaga, Department of Genetics, Physical 
Anthropology and Animal Physiology, University of the Basque Country, Bilbao, 
Spain), p8xGTIIC–Luc (TEAD reporter, obtained from Addgene, Catalog No. 
34615), pFA2–cJun (JNK reporter, obtained from Stratagene), pSRE–Luc (SRF 
reporter, Agilent, Catalog No. 219081), and pRL–SV40 (Renilla luciferase, obtained 
from Promega, Catalog No. E2231). All plasmids were DNA sequence verified. 
In silico analyses of public gene expression data 
R (version 3.5.1) and Perl were used to carry out the statistical analyses and data 
processing, respectively. Signal intensity values were obtained from CEL files after 
robust multichip average (RMA). Differentially expressed genes were identified 
using linear models for microarray data (Limma). Adjusted P values for multiple 
comparisons were calculated applying the Benjamini–Hochberg correction (false 
discovery rate, FDR). The GEO datasets GSE45216 and GSE13355 (human cSCC), 
GSE30784 (human oSCC) and GSE21264 (mouse cSCC) were used to identify the 
RHO GEFs differentially expressed in SCC tumors as well as to obtain the mRNA 
expression levels according to pathological status. The dataset GSE52954 was used 
to assess the expression of RHO GEFs during keratinocyte differentiation. The 
TCGA hnSCC dataset was accessed and analyzed through the TCGAbiolinks R 
package. In all cases, a 0 to 1 normalization of the expression values was applied for 
representation purposes. A T–ALL dataset GSE26713 was used as control for SCC–
specific deregulation. Overall survival analyses were performed through Kaplan–
Meier estimates using the GSE41613 dataset. The median of the expression 
distribution for each transcript was used to establish the low and high expression 
groups and, subsequently, the Mantel–Cox test was applied to statistically validate 
the differences between the survival distributions. Correlation matrices were 
calculated from the indicated expression matrices using the corrplot R package. 










human genomic data from the UCSC Genome Browser and public copy-number 
variation data from GISTIC analyses of the TCGA hnSCC dataset. The GEF-based 
gene network reverse engineering was performed through ARACNE [142] using the 
adaptative partitioning algorithm for mutual information inference, and setting the 
indicated GEFs as hubs and a P value threshold of 10–10. The resulting networks 
were represented using the Cytoscape software [143] and functionally analyzed 
through Metascape [144]. For the discovery of transcription factor binding motifs in 
the promoters of the coregulated genes, the iRegulon software was used [145]. A 
collection of 9,713 position weight matrices (PWMs) was applied to analyze 10 kb–
long DNA sequences that were centered around the transcriptional start sites. Using 
as criteria a maximum false discovery rate (FDR) on motif similarity below 0.001, 
we performed motif detection, track discovery, motif–to–factor mapping, and target 
detection. The ternary and radar plots used to represent GEF catalytic specificity and 
subcellular localization were generated with the R Ternary and fmsb packages and 
the data available in [146]. 
 
Immunoprecipiation experiments 
Healthy mucosa, when included in the experiments, where obtained from the hnSCC 
patients (due to this, they were assigned the same identification number shown in 
Figure 1.3). Tumoral and healthy tissues were mechanically homogenized in RIPA 
buffer (10 mM Tris–HCl [pH 8.0], 150 mM NaCl, 1% Triton X–100 (Sigma, Catalog 
No. X100), 1 mM Na3VO4 (Sigma, Catalog No. S6508), 1 mM NaF (Sigma, Catalog 
No. S7920), and a mixture of protease inhibitors (Roche, Catalog No. 11836145001) 
using a gentleMACS dissociator (Miltenyi Biotec, Catalog No. 130–093–235) and 
gentleMACS M tubes (Myltenyi Biotec, Catalog No. 130–096–335). Extracts were 
precleared by centrifugation at 13,200 rpm for 10 min at 4 ºC. Protein concentration 
in the resulting supernatants was quantified using the Bradford reactive (Bio–Rad, 
Catalog No. 5000006). 400 µg of protein extracts in a final volume of 500 µl of 
RIPA buffer were incubated with 1.5 µl of a homemade antibody to Vav2 (Lab 
catalog No. 580–2) for 2 hours at 4 ºC in a rotating wheel. Immunocomplexes were 
collected with 35 µl of Gammabind G–Sepharose beads (GE Healthcare, Catalog No. 
GE17–0885–01) at 50% concentration for another 2 hours at 4 ºC in a rotating wheel. 










SDS–PAGE buffer, boiled for 5 min, and subjected to Western blot analyses as 
indicated below. 
Western blotting 
In the case of tissue extracts, samples were transferred to RIPA buffer and 
mechanically homogenized using the gentleMACS dissociator. In the case of 
keratinocytes maintained in culture, cells were washed with chilled phosphate 
buffered saline solution and then directly lysed in RIPA buffer at 4 ºC. Extracts were 
precleared by centrifugation at 13200 rpm for 10 min at 4°C, denatured by boiling in 
SDS–PAGE sample buffer, separated electrophoretically, and transferred onto 
nitrocellulose filters using the iBlot Dry Blotting System (ThermoFisher, Catalog 
No. IB21001). Membranes were blocked in 5% bovine serum albumin (Sigma, 
Catalog No. A7906) TBS–T (25 mM Tris–HCl (pH 8.0), 150 mM NaCl, 0.1% 
Tween–20 (Sigma, Catalog No. P7949) for at least 1 hour and then incubated 
overnight at 4 ºC with the appropriate antibodies to Vav2 (1:1000 dilution, 
homemade), GFP (1:5000 dilution, Covance, Catalog No. MMS–118P), the 
hemagglutinin (HA) epitope (1:1000 dilution, Cell Signaling, Catalog No. 3724), 
Rac1 (1:1000 dilution, BD Biosciences, Catalog No. 610651), RhoA (1:1000 
dilution, Cell Signaling, Catalog No. 2117), Cdc42 (1:1000 dilution, Santa Cruz 
Biotechnology, Catalog No. sc–87), c–Myc (1:1000 dilution, Merck, Catalog No. 
06–340), and tubulin α (1:2000 dilution, Calbiochem, Catalog No. CP06). After 
three washes with TBS–T to eliminate the primary antibody, the membrane was 
incubated with the appropriate secondary antibody (1:5000 dilution, GE Healthcare) 
for 30 min at room temperature. Immunoreacting bands were developed using a 
standard chemiluminescent method (ThermoFisher, Catalog No. 32106). Blots were 
quantified using the ImageJ software. When indicated, filters were stained with 
Ponceau S solution (Sigma, Catalog No. P7170). 
Analysis of mRNA abundance 
Total RNA was extracted using NZYol (NZYtech, Catalog No. MB18501) and 
quantitative RT–PCR performed using the Power SYBR Green RNA–to–CT 1–Step 
Kit (Applied Biosystems, Catalog No. 4389986) and the StepOnePlus Real–Time 










using the StepOne software (Applied Biosystems). We used the abundance of the 
endogenous GAPDH mRNA as internal normalization control. Primers used for 
transcript quantitation included: 5’–GAC GGG GAA CTG AAA GTC CG–3’ 
(forward, VAV2), 5’–TTT TCC CGT GAG ACT TCT TGA C–3’ (reverse, VAV2), 
5’–ATG GCC TTC CGT GTC CCC ACT G–3’ (forward, GAPDH), 5’–TGA GTG 
TGG CAG GGA CTC CCC A–3’ (reverse, GAPDH), 5’–AAG TAC CTC AGC 
CTC CAG CA–3’ (forward, Nanog), 5’–GTG CTG AGC CCT TCT GAA TC–3’ 
(reverse, Nanog), 5’–TGC ACC ACC AAC TGC TTA GC–3’ (forward, Gapdh), 5’–
TCT TCT GGG TGG CAG TGA TG–3’ (reverse, Gapdh), 5’–TCC TCT TCC AGT 
CCT TAA AGC–3’ (forward, ECT2), 5’–GTT TCA ATC TGA GGC ATC TCT 
TCT–3’ (reverse, ECT2), 5’–GCT CCT AGA GAT TGC CCG TC–3’ (forward, 
FARP1), 5’–CCT GGT ACG CAC TAT TGG CA–3’ (reverse, FARP1), 5’–CCT 
CTG TGC ACC GGA GTA TG–3’ (forward, FGD6), 5’–CTG GGA TGC TCC 
TGA ACT GG–3’ (reverse, FGD6), 5’–CGG GAA GGA CTC AGC AAC AA–3’ 
(forward, TRIO), 5’–GCC TCT CCC AGG TCA CTG TA–3’ (reverse, TRIO), 5’–
GAT CCA GCA GCT GAC CAA GA–3’ (forward, ARHGEF10L), 5’–CTG GCC 
CCT GTG GTT GG–3’ (reverse, ARHGEF10L), 5’–ACA GGC TAC GCA ACA 
GGT TC–3’ (forward, ITSN2), 5’–AGC CCC CAG CAT TAA CCA TT–3’ (reverse, 
ITSN2), 5’–GAC CCC TCT CAG ACA AAA GC–3’ (forward, KALRN), 5’–ATC 
TGC TCG AAG AGG AAC ACG–3’ (reverse, KALRN), 5’–TGG GAC ATG TGA 
AGC CAG AC–3’ (forward, TIAM1), 5’–GAA TGC GCC AAA AAC CCC AT–3’ 
(reverse, TIAM1), 5’–GCT TAA CAA CCT CCG GGC G–3’ (forward, VAV3), 5’–
GAA GGG CCT GAT TCC TGT GG–3’ (reverse, VAV3). 
Histological studies  
Tissues were extracted, fixed in 4% paraformaldehyde, paraffin embedded, cut in 2–
3 µm thick sections, and stained with hematoxylin–eosin. Images were captured 
using an Olympus BX51 microscope coupled to an Olympus DP70 digital camera. 
The thickness of the epidermal and/or dermal layers was measured in vertical cross–
sections using the software ImageJ. In the case of tumor sections, they were analyzed 












Immunohistochemical staining was performed using a Ventana Discovery Ultra 
instrument (Roche, Catalog No. 05987750001). Paraffin–embedded sections were 
dewaxed, subjected to either citrate buffer [pH 6.0] or Tris EDTA [pH 8.0] for heat–
induced antigen retrieval, and incubated for 40 min with the appropriate primary 
antibody to c–Fos (1:50 dilution, Santa Cruz Biotechnology, Catalog No. sc–
166940), c–Myc (1:50 dilution, Abcam, Catalog No. ab32072), YAP (1:200 dilution, 
Novus Biologicals, Catalog No. NB110–58358), Cyclin D1 (1:200 dilution, Roche, 
Catalog No. 790–4508), keratin 14 (1:300 dilution, Biolegend, Catalog No. 905301), 
involucrin (1:100 dilution, Sigma, Catalog No. I9018) or BrdU (1:100, BD, Catalog 
No. 347580). For standard staining, the Discovery OmniMap anti–Rb HRP detection 
system (Roche, Catalog No. 760–4311) was used for detection and hematoxylin for 
counterstaining as indicated by the manufacturer. For immunofluorescent studies, we 
incubated the sections in a humid chamber for 1 hour with secondary antibodies to 
rabbit and mouse IgGs labeled with Alexa Fluor 488 (1:200 dilution, ThermoFisher, 
Catalog No. A21206) and Cy3 (1:200 dilution, Jackson ImmunoResearch, Catalog 
No. 115–165–146), respectively. A 5–minute incubation with DAPI (Sigma, Catalog 
No. D9542) or rhodamine-labeled phalloidin (Invitrogen; diluted 1:200 in TBS–T 
and 2% bovine serum albumin) was performed for counterstaining. Samples were 
analyzed with a Leica TCS SP5 confocal microscope. Images were captured with 
LAS AF software (version 2.6.0.72266, Leica). Quantitation of 
immunohistochemical signals were done using the ImageJ software by adjusting the 
signal threshold to the staining intensity and measuring the area of the resulting 
particles. 
Three–dimensional histotypic cultures 
Exponentially growing keratinocytes maintained in CnT–Prime medium were 
detached using accutase, centrifuged at 300 xg for 5 min at room temperature, and 
counted. 2 x 105 cells were seeded onto polycarbonate inserts (ThermoFisher, 
Catalog No. 140620) and cultured for two days in CnT–Prime medium. Upon 
confluency, the medium was changed to 3D–Barrier (CellnTec, Catalog No. CnT–
PR–3D) and the air–lift was performed according to the manufacturer's instructions. 










finally processed for histological study as indicated above. When indicated, the 
inhibitors and corresponding vehicles were applied in the sixth day after carrying out 
the airlift and refreshed with the medium changes indicated above. Inhibitors used 
included FRAX597 (5 nM, Selleckchem, Catalog No. S7271), Y–27632 2HCl (1 
µM, Selleckchem, Catalog No. S1049), 1A116 (500 nM) [147], 10058–F4 (500 nM, 
Selleckchem, Catalog No. S7153), and verteporfin (200 nM, Selleckchem, Catalog 
No. S1786). Concentrations of inhibitors were selected based on the induction of 
minor effect in the histotypic structures formed by control cells. 
Lentiviral–mediated expression of proteins in human keratinocytes 
For the generation of stable cell clones, lentiviral particles were produced in 
HEK293T cells cultured in DMEM (supplemented with 10% fetal bovine serum and 
2 mM L–glutamine) and subsequently concentrated using the LentiX concentrator kit 
(Clontech, Catalog No. 631232). Keratinocytes were then infected with control and 
protein–encoding lentiviral particles in KGM–Gold medium in the presence of 8 
µg/ml of polybrene (Sigma, Catalog No. H9268) and selected by either antibiotic 
resistance or EGFP expression by flow cytometry. In the latter case, we used a 
FACSAria III flow cytometer (BD Biosciences) for cell purification. Proper protein 
expression was assessed by Western blot.  
Rho GTPase activation assays 
Total cellular lysates were obtained as above, snap frozen, thawed, quantified for 
total protein concentration, and analyzed using the Rac1, RhoA and Cdc42 G–LISA 
assay kits according to the manufacturer's instructions (Cytoskeleton, Catalog No. 
BK135).  
RNA extraction and transcriptome profiling  
Whole epidermis or FACS-purified epidermal stem cells were lysed in RLT buffer 
and RNA was extracted using the QIAGEN RNeasy Mini (QIAGEN, Catalog No. 
74104) or Micro Kit (QIAGEN, Catalog No. 74004), respectively, according to 
manufacturer’s instructions. Purified RNA was processed as indicated elsewhere [97] 










In silico analyses of mouse epidermis expression microarray data 
Initial data processing was carried out as indicated for the human data (see above). 
Gene Ontology and KEGG pathways enrichment analyses were performed using 
DAVID and ToppFun. GSEA was performed using gene set permutations (n = 1000) 
for the assessment of significance and signal–to–noise metric for ranking genes. The 
gene sets used included signatures related to: epidermal differentiation (GSE52954); 
SCC stem cells (GSE29328); embryonic stem cells (GSE10423); cSCC cells 
(GSE5576); and metastatic oSCC cells (GSE72939). We also used lists for 
transcriptional targets for AP1 [148], c-MYC [149], E2F (signature #M40 from the 
Molecular Signatures Database, Broad Institute), NFY (signature #C3:TFAC:0178 
from the Molecular Signatures Database, Broad Institute), YAP/TAZ/TEAD 
(GSE66083), and FOXO (signature #C3:TFAC:0256 from the Molecular Signatures 
Database, Broad Institute). To evaluate the similarity between the transcriptional 
programs activated by Vav2Onc and those differentially regulated in the indicated 
SCC and clinical conditions, the datasets GSE45216 and GSE13355 (human cSCC), 
GSE30784 (human oSCC) and GSE21264 (mouse cSCC) were used as indicated 
above. To assess conservation of the Vav2Onc transcriptional signature across tumors, 
a 1.5–fold change threshold was used. Heatmaps were generated using the heatmap3 
package. To evaluate the enrichment of the Vav2Onc gene signature across SCC 
tumors, ssGSEA were used. To assess the specificity of the Vav2Onc–Sig, a principal 
component analysis was performed using the datasets indicated in the corresponding 
figure legend. For the identification of the Vav2Onc–driven prognostic signature, the 
Cox proportional–hazards regression model was applied using the survival R 
package. Survival analyses according to the Vav2Onc–driven prognostic signature 
enrichment were performed as indicated above, using datasets from the GEO 
(GSE41613) and the TCGA (hnSCC collection). For the discovery of transcription 
factor binding motifs in the promoters of the coregulated genes, the iRegulon 
software was used as indicated above [145]. Circos plots were generated using the 
OmicCircos package implemented with mouse genomic data from the UCSC 
Genome Browser (https://genome.ucsc.edu), gene ontology annotation from the 
Gene Ontology Consortium (http://www.geneontology.org), and transcription factor 
annotation from the iRegulon tool. To evaluate the correlation of c–MYC or YAP 










to VAV2 expression levels (low, medium, and high, established by quantiles) and 
calculated the ssGSEA enrichment score for the aforementioned signatures. 
Generation of induced pluripotent stem cells from primary keratinocytes 
Retroviral particles encoding the Yamanaka’s factors were used to infect primary 
keratinocytes obtained from neonate mice in the presence of polybrene (8 µg/ml) 
and, after two days, transferred to an iPSC medium composed of DMEM–
GlutaMAX (ThermoFisher, Catalog No. 31966–021), 15% knockout serum 
replacement (ThermoFisher, Catalog No. 10828–028), 1x nonessential amino acids 
(ThermoFisher, Catalog No. 11140–035), 100 µM 2–mercapthoethanol 
(ThermoFisher, Catalog No. 31350–010), and 1 x 103 u/ml LIF (Millipore, Catalog 
No. ESG1107). Three days later, cells were collected using accutase and seeded on 
feeder cell layers generated as indicated elsewhere [150]. iPS cell colonies were 
allowed to grow for two weeks, with daily medium changes, and finally stained with 
an alkaline phosphatase assay kit (Sigma, Catalog No. AB0300) according to the 
manufacturer’s instructions. The generation of bona–fide iPS cells was further 
confirmed using qRT–PCR analysis to detect Nanog expression. 
 
Promoter activation assays 
We utilized luciferase reporter plasmids to evaluate the activation status of the 
interrogated transcriptional factors of our study. To this end, exponentially growing 
human keratinocytes were transiently transfected with 40 ng of the pRL–SV40 
vector encoding the Renilla luciferase for intersample normalization, 2 µg of the 
appropriate EGFP and EGFP–Vav2 encoding vector, and 2 µg of the appropriate 
firefly reporter plasmids containing the firefly luciferase gene under the regulation of 
AP1– (pAP1–Luc), c–Myc– (pBV–Myc–Del1–Luc), E2F– (pGL2–Chk1–WT–Luc), 
and TEAD– (p8xGTIIC–Luc) responsive promoters. After 24 hours, cells were lysed 
with Passive Lysis Buffer (Promega, Cat No. E1960) and luciferase activities 
determined using the Dual Luciferase Assay System (Promega, Cat No. E1960). In 
all cases, the values of firefly luciferase activity obtained in each experimental point 
were normalized taking into account the activity of the Renilla luciferase obtained in 










blot to assess the appropriate expression of the ectopically expressed proteins in each 
case. Values are represented in the figures as the n–fold change of the experimental 
sample relative to the activity shown by control cells (which was given an arbitrary 
value of 1 in each case). When needed, these experiments included the use of 
chemical inhibitors in concentrations identical to those used in the 3D histotypic 
cultures. 
shRNA–mediated transcript knockdown 
To target the mRNAs encoding the different GEFs, we infected the indicated cell 
lines with lentiviruses encoding either empty (TR1.5–pLKO–1–puro, Sigma, Catalog 
No. SHC001) or a number of independent shRNAs against VAV2 
(TRCN0000435647, referred to in the figures as shRNA#1; TRCN0000436728, 
referred to in the figures as shRNA#2; TRCN0000048227, referred to in the figures 
as shRNA#3; TRCN0000418821, referred to in the figures as shRNA#4 and 
TRCN0000419630, referred to in the figures as shRNA#5), ECT2 
(TRCN0000047686, referred to in the figures as shRNA#1; TRCN0000299365, 
referred to in the figures as shRNA#2), FARP1 (TRCN0000303352, referred to in 
the figures as shRNA#1; TRCN0000047243, referred to in the figures as shRNA#2), 
FGD6 (TRCN0000420570, referred to in the figures as shRNA#1; 
TRCN0000418076, referred to in the figures as shRNA#2), TRIO 
(TRCN0000010561, referred to in the figures as shRNA#1; TRCN0000000871, 
referred to in the figures as shRNA#2), ARHGEF10L (TRCN0000433949, referred 
to in the figures as shRNA#1; TRCN0000416149, referred to in the figures as 
shRNA#2), ITSN2 (TRCN0000381122, referred to in the figures as shRNA#1; 
TRCN0000002385, referred to in the figures as shRNA#2), KALRN 
(TRCN0000001428, referred to in the figures as shRNA#1; TRCN0000001429, 
referred to in the figures as shRNA#2), TIAM1 (TRCN0000256946, referred to in the 
figures as shRNA#1; TRCN0000256948, referred to in the figures as shRNA#2) or 
VAV3 (TRCN0000047701, referred to in the figures as shRNA#1; 
TRCN0000047702, referred to in the figures as shRNA#2). These lentiviral vectors 
were obtained from Sigma. Lentiviral particle production and infections were done 
as indicated above. Transduced cells were puromycin selected as described 










JNK and SRF activity assays in COS1 cells 
For JNK activation assays, exponentially growing COS1 cells were transfected with 
liposomes (Lipofectamine 2000, ThermoFisher, Catalog No. 11668019) with 1, 0.5, 
and 2 µg of the pFR–Luc, pFA2–cJun, and the appropriate experimental expression 
vector, respectively. For SRF activation assays, COS1 cells were transfected as 
above with 1 µg of pSRE–luc, 1 ng of pRL–SV40, and 1 µg of the appropriate 
experimental vectors. Luciferase activities were determined 36 hours after the 
transfection step as described earlier. In all cases, the abundance of the ectopically 
expressed proteins under each experimental condition was verified by analyzing 
aliquots of the cell extracts used in the luciferase experiments by immunoblot. 
Cytoskeletal change assays 
COS1 cells exponentially growing in 6–well culture plates were transfected with 1 
µg of the plasmid of interest with Lipofectamine 2000. After 24 hours, cells were 
trypsinized, plated onto 12–mm diameter coverslips (Menzel–Glaser, Catalog No. 
11778691) pre–treated for 10 min with poly–L–Lysine (1 µg/ml, Sigma, Catalog No. 
P4707), and then cultured for 12 to 24 hours. Cells were then fixed in 4% 
formaldehyde in phosphate buffered saline solution for 15 min, washed twice with 
phosphate buffered saline solution, permeabilized in 25 mM Tris–HCl (pH 8.0) 
containing 0.5% Triton X–100 (Sigma) for 10 min, washed three times with TBS–T, 
and blocked for 15 min with 2% bovine serum albumin in TBS–T. After a 20–min 
long incubation with rhodamine–labeled phalloidin (Invitrogen; diluted 1:200 in 
TBS–T and 2% bovine serum albumin) to visualize the F–actin cytoskeleton, cell 
preparations were washed thrice with TBS–T, stained with DAPI (Invitrogen, 
Catalog No D1306) for 5 min to visualize the nuclei, and mounted onto microscope 
slides with Mowiol (Calbiochem, Catalog No 9002–89–5). Samples were analyzed 
with a Leica TCS SP5 confocal microscope. Images were captured with LAS AF 
software (version 2.6.0.72266, Leica). 
Whole mount immunohistochemical analyses 
Tail skin was incubated in 5 mM EDTA (ethylenediaminotetraacetic acid) in PBS at 










temperature, the epidermis was then fixed in 4% paraformaldehyde for 2 hours, 
permeabilized in 0.2% Triton X-100 (Sigma, Catalog No. T8787) for 15 min and 
blocked in 2% horse serum (ThermoFisher, Catalog No. 16050122) for 30 minutes, 
with 10-minute washing intervals in PBS between each step. Incubation with the 
primary antibody was performed in 2% horse serum overnight at room temperature 
using the following antibodies: BrdU (1:100, BD, Catalog No. 347580), Ki67 (1:100, 
Novocastra, Catalog No. NCL-L-Ki67-MM1), K14 (1:400, Covance, Catalog No. 
PRB-155P). Secondary antibody incubation was performed on the next day under the 
same conditions with Alexa Fluor 488 (1:400, Invitrogen, Catalog No. A21202) and 
Cy3 (1:400, Jackson Immunoresearch, Catalog No. 111-165-144). After washing, the 
preparations were stained with DAPI for 1 hour and mounted using Mowiol 
(Calbiochem, Catalog No 9002–89–5). Samples were analyzed with a Leica TCS 
SP5 confocal microscope. Images were captured with LAS AF software (version 
2.6.0.72266, Leica). 
Epidermal stem cell isolation 
The isolation of epidermal stem cells was carried out as previously described [151]. 
Briefly, back skin was digested in 0.25% trypsin (ThermoFisher, Catalog No. 
25200056) overnight at 4ºC to collect the keratinocytes from the epidermis. This cell 
suspension was then filtered, resuspended in EMEM (Lonza, Catalog No. BE06-
174G) with 15% fetal bovine serum (ThermoFisher, Catalog No. 10500064) and 
incubated for 30 minutes on ice with biotin-conjugated anti-CD34 (1:50, 
eBioscience, Catalog No. 13-0341-85) followed by another 30-minute incubation 
with APC-conjugated streptavidin (1:300, BD Biosciences, Catalog No. 554067) and 
PE-conjugated anti-CD49f (1:200, AbD Serotec, Catalog No. MCA699PE). DAPI 
(4’,6-diamidino-2-phenylindole) staining was used to exclude dead cells. Positive 
cells for CD34 and CD49f were isolated using a FACSAria III flow cytometer (BD 
Biosciences) and analyzed with the FlowJo software. 
Epidermal stem cell proliferation 
DNA replication in proliferating cells was assessed using the Click-iT EdU Alexa 
Fluor 647 Flow Cytometry Assay Kit (ThermoFisher, Catalog No. C10424) 










Colony formation assays 
Keratinocytes were isolated as indicated before, counted and plated in six-well plates 
at a density of 500 cells per well in CnT07 medium. Upon colony formation after 10-
14 days, cells were fixed with 4% paraformaldehyde for 10 minutes and stained with 
Giemsa (1:10, Merck, Catalog No. 32884) for another 10 minutes. Plates were 
washed with distilled water, left to dry and colonies were quantified. 
Standardized in silico analyses of epidermal stem cell expression microarray 
data 
Initial data processing was carried out as indicated for the human and mouse 
epidermis data (see above). The heatmap3 package was used to generate the 
expression heatmaps for the indicated genes. Functional annotation was performed 
using Metascape [144] for biological processes and ToppFun [152] for molecular 
functions. A FDR q-value of 0.05 was set as threshold for statistical significance. 
GSEA was carried out as described above with the EpSC-associated gene sets 
obtained from [153]. Single-sample Gene Set Enrichment Analysis (ssGSEA) [154, 
155] was used to calculate the fitness of different hallmark [156] and epidermal stem 
cell signatures [153] across time and genotypes. The time-course enrichment scores 
for either these signatures or individual transcripts were used to build the signature 
correlation matrices, obtained through the corrplot R package. Correlations were 
considered statistically significant when the Pearson coefficient corresponded to a P 
value below 0.05. Functional clusters were established when every pair-wise 
correlation within a group of signatures was found significant. Known functional 
interactions among relevant genes were obtained through the String tool [157]. 
Cytoscape software was used to perform network data integration and visualization 
[143]. For the discovery of transcription factor binding motifs in the promoters of the 
co-regulated genes, the iRegulon software was used as indicated above [145]. 
Establishment of time-course gene expression patterns in epidermal stem cells 
As described before [158], both Chi-squared and fold change thresholds were used to 
establish static and dynamic probesets. Briefly, for each probeset, a Chi-squared test 
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where !!  is the mean expression of the gene for the microarray triplicates for 
each time point i,  ! is the overall mean expression across all time points, and n is 
the number of time points. For those probesets satisfying P(!!) < 0.01, a fold change 
>= 2 requirement was empirically established. 
Unsupervised soft clustering with the Mfuzz R package [159] was used for 
the identification of time-course expression profiles. After standarization of the 
expression values for Euclidian space clustering, we applied the mfuzz function with 
a fuzzifier value of 1.25 and a ranging number of cluster centers to determine the 
optimal number of non-overlapping expression patterns. For the inclusion of a 
probeset in a particular cluster, the membership value threshold was set to 0.5. The 
resulting expression profiles were named according to the position of the main 
positive (+) and negative (–) enrichments (peaks), i.e., 0.6 = 0.6 months old, 1 = 1 
month old, 2.5 = 2.5 months old, 4 = 4 months old, 6 = 6 months old, 12 = 12 months 
old. 
To evaluate how Vav2Onc activity affects EpSC transcriptional dynamics, the 
fluctuation of each dynamic probeset between WT and Vav2Onc genotypes was 
analyzed. Using the Cytoscape software [143], we represented the results as a 
network where the nodes represent expression patterns and the edges (arrows) 
indicate how dynamic transcripts behave in the Vav2Onc context when compared to 
the WT. Node color, hue and size were set according to genotype, connectivity and 
number of probesets, respectively. The inner ring was used to specify the fraction of 
genotype-specific dynamic probesets within the pattern. Edge thickness was 
established according to the number of transcripts that are shared between two nodes. 
The sensitivity for edge representation was set to 10% of the pattern size. 
For the visualization of expression and enrichment data, a 0–1 normalization 














Weighted correlation network analyses  
In order to find the best representatives of every gene expression pattern, the 
WGCNA R package was applied [160]. We constructed each weighted gene network 
from the corresponding expression matrix through the blockwiseModules function. 
The pickSoftThreshold function was used to select the soft thresholding power 
according to network topology. Consensus module detection within each expression 
pattern was omitted and kept to one module as the number of clusters had been 
already optimized. The heatmap plot depicting the adjacency matrix was created with 
the TOMplot function. To calculate the intramodular connectivity for each gene, we 
computed the whole network connectivity for each expression pattern through the 
intramodularConnectivity function. Hubs were defined as the 10% most connected 
genes within each expression pattern. The known functional interactions among hubs 
were obtained through the String tool [157] and represented using Cytoscape [143]. 
Determination of cell proliferation in vitro 
Proliferation was measured at the indicated time points using the 3-(4,5-
dimethylthiazol-2-yl) 2,5-diphenyltetrazolium bromide (MTT) method. To this end, 
the culture medium of each 200-mm2 well was replaced by 250 µL of the MTT 
solution (0.5 mg/mL). After 1 hour at 37ºC in a 5% CO2 atmosphere, the MTT 
solution was replaced by 500 µL of DMSO in order to dissolve the formazan crystals 




QUANTIFICATION AND STATISTICAL ANALYSES 
Statistics 
The number of biological replicates (n), the type of statistical tests performed, and 
the statistical significance are indicated for each experiment either in the figure 
legends or in the main text. Data normality and equality of variances were analyzed 
with Shapiro–Wilk and Bartlett’s tests, respectively. Parametric distributions were 










way ANOVA followed by either Dunnett’s (when comparing more than two 
experimental groups with a single control group) or Tukey’s HSD test (when 
comparing more than two experimental groups with every other group). For those 
analyses where two independent variables were considered, two-way ANOVA 
followed by Sidak’s multiple comparisons test was applied. Nonparametric 
distributions were analyzed using either Mann–Whitney (for comparisons of two 
experimental groups) or the Kruskal–Wallis followed by Dunn’s (for comparisons of 
three or more than three experimental groups) tests. The chi–squared test was used to 
determine the significance of the differences between expected and observed 
frequencies. In all cases, values were considered significant when P ≤ 0.05. Data 















































Vav2 upregulation is a functionally relevant event in SCC carcinogenesis 
We have demonstrated in this thesis that the RHO GEF VAV2 constitutes a signaling 
modifier intrinsically associated with the maintenance of stem cell-like traits in 
different populations of epidermal and oral squamous cells. This VAV2-driven 
stemness-associated molecular program is frequently exploited by cSCC and hnSCC 
tumor cells, where the abundance of both VAV2 and VAV2 transcripts becomes 
strongly upregulated. Importantly, we have proved using histotypic cultures and 
xenotransplantation experiments that patient-derived SCC cells require these high 
levels of endogenous VAV2 for their tumorigenic fitness. Consistent with this, we 
have also found that the abundance of VAV2 and its molecular signature correlates 
with the poor prognosis of oSCC patients in a comparable manner to bona–fide SCC 
drivers such as the EGFR, KRAS, ACTL6A, c–MYC, and NOTCH family members 
[54, 60]. However, unlike those cases, the deregulation of the VAV2 pathway in 
SCC is not associated with locus-specific genetic alterations. In this regard, the 
molecular basis for the aberrant upregulation of VAV2 in these tumors remains to be 
addressed. Possible explanations include the amplification of super–enhancers and 
the spurious activation of transcriptional factors. Given that the fold changes in 
VAV2 protein are much larger than those found in its transcripts in both patient 
samples and patient–derived cells, it is also possible that processes associated with 
increased mRNA translation could contribute to the enhancement of VAV2 
signaling.  
Regardless of the mechanism mediating such VAV2 upregulation, it targets 
the VAV2 locus specifically as the genes located in its vicinity do not share the same 
dysregulation pattern. This phenomenon is also tumor-specific since it is virtually 
restricted to cSCC and hnSCC, while other squamous tumors such as lSCC or 
ceSCC, as well as most of the tumors from pan-cancer collections, do not show 
alterations in VAV2 levels. Importantly, this deregulation takes place very early 
during cSCC and hnSCC tumor evolution, as inferred from the detection of 
upregulated VAV2 in premalignant lesions such as actinic keratosis and oral 
epithelial dysplasias. This indicates that the upregulation of VAV2 is not the mere 
consequence of the genomic- and transcriptomic-wide turmoil present in full-blown 












Consistent with the aforementioned findings, we have shown using a knockin 
gain-of-function mouse model that upregulated Vav2 signaling promotes a 
hyperproliferative and undifferentiated phenotype in epidermal and oral squamous 
epithelia. In the case of the skin, this is also accompanied by epidermal inclusion 
cysts, orphan sebaceous glands and an abnormally high density of hair follicles. Even 
though these alterations do not lead per se to tumorigenesis in the cancer-resistant 
C57BL/6 mouse strain, aged Vav2Onc mice in mixed genetic backgrounds do develop 
skin tumors, thus demonstrating that in some contexts upregulation of Vav2 activity 
can be sufficient to drive tumor formation (data not shown). Perhaps more 
importantly, hyperactivation of Vav2 favors tumor formation, progression and poor 
prognosis regardless of the mouse model tested when it is combined with additional 
genetic lesions. This mutated scenario mimics the genomic erosion intrinsic to 
human SCC tumors, offering a more faithful and clinically-relevant model on the 
impingement of VAV2 signaling on SCC carcinogenesis. 
We are fully aware of the inherent limitations of using a constitutive knockin 
mouse model for a gene as widely expressed as Vav2. However, through skin 
xenograft experiments we have demonstrated that the epidermal phenotype of 
Vav2Onc mice stems exclusively from keratinocytes. Furthermore, when grown in 3D 
histotypic cultures, both mouse and human keratinocytes expressing hyperactive 
Vav2 recapitulate the hyperplastic condition seen in the skin of the Vav2Onc mouse 
model. Importantly, not only does the latter finding reflect the autonomy of such 
phenotype, but it also proves formally that it stems from keratinocytes that are not 
associated to the hair follicle. 
Besides its role in keratinocytes, it should be indicated that both published 
and unpublished data from our group have shown that Vav2 can signal from many 
other cell lineages and cause an array of pathological disorders ([118, 119, 134]). 
Among these, hyperactivation of Vav2 in fibroblasts leads to dermal dysplasia and, 
interestingly, to the spurious formation of hair follicles and epidermal inclusion 
cysts. Although the underpinnings of this phenotype have yet to be addressed, the 
intimate crosstalk that takes place between keratinocytes and fibroblasts via growth 
factors and cytokines seems prima facie a promising lead [186]. Consistent with this 
possibility, Vav2 is known to regulate the expression of a large number of these 









not shown). Whether this represents an additional mechanism by which this GEF can 
contribute to SCC carcinogenesis will be investigated in the future. 
 
Vav2 is a key mediator of stemness in epidermal and oral squamous cells 
Our 3D histotypic models have allowed us to explore the molecular apparatus 
mediating Vav2 signaling in the squamous cell context. We have found that Vav2 
elicits its epidermal phenotype in a catalysis-dependent manner through the 
activation of Rac1 and RhoA. Importantly, the activation of these two GTPases has 
to occur concurrently in order to fully recapitulate the Vav2Onc phenotype. In line 
with this, we have encountered that their respective effector kinases, such as Pak or 
Rock, are necessary but not sufficient to trigger the Vav2Onc-induced epidermal 
disorders (data not shown). Since Rac1 and RhoA signaling pathways engage 
mutually inhibitory loops in several cellular contexts [187], the cooperation between 
both GTPases driven by Vav2 probably involves some kind of spatial segregation. 
The activation of this Vav2-governed signaling cascade triggers a 
downstream transcriptional program intimately involved in the promotion of 
keratinocyte proliferation and undifferentiation. As a result, keratinocytes endowed 
with high Vav2 activity develop a stem cell-like molecular profile. In line with this, 
we have found that endogenous Vav2 is highly expressed in epidermal progenitors 
located at the basal layer of the squamous epithelium (data not shown). Such Vav2-
driven transcriptional program is frequently engaged by human SCC tumor cells and, 
importantly, is strongly associated to patient survival. Using a series of bioinformatic 
approaches, we have been able to distill this association into a robust 41-gene 
minimal prognostic signature that has been validated using data from over 600 
hnSCC patients.  
Further in silico analyses have revealed that the Vav2–driven transcriptional 
program is triggered via the stimulation of transcription factors (AP1, c–Myc, E2F, 
Nfy, Yap/Tead) directly involved in the orchestration of gene expression changes 
associated with stem cell–like regenerative proliferation and delays in cell 
differentiation [54, 60, 145, 188-191]. Both our gain– and loss–of–function 











expression of the aforementioned transcription factors in hyperplastic epithelia, 
SCCs, and patient–derived cells.  
Using patient-derived data, we have found that these correlations are 
especially robust in the case of c–Myc and Yap factors. Consistent with this, we have 
proved that these two transcriptional regulators play pivotal roles in the Vav2-
mediated induction of keratinocyte proliferation and undifferentiation, respectively. 
In this regard, while it has been previously reported that Rac1 and RhoA can drive 
the activation of Yap/Taz [192], the mechanism employed by Vav2 in order to 
trigger c–Myc activation is still to be fully understood. Although it was initially 
reported in mice that Rac1 regulates c–Myc negatively through Pak2-mediated 
phosphorilation [87], this finding has been challenged by later studies [88]. 
According to our data, the fast cycling versions of Rac1 and RhoA are only able to 
induce a mild upregulation of c–Myc in histotypic cultures, much lower than in the 
case of Vav2Onc cells. However, when both hyperactive GTPases are expressed 
simultaneously, the abundance of this transcription factor becomes exacerbated, thus 
suggesting that the synergism between Rac1 and RhoA pathways might mediate the 
induction of c–Myc. In any case, formal demonstration of this hypothesis will require 
further validation. 
 
VAV2 is a potential therapeutic target in squamous cell carcinoma 
Cross–platform comparative analyses of the Vav2Onc–driven transcriptional program 
has revealed that around 40% of its transcripts show the opposite transcriptional 
behavior in the TPA-treated skin of Vav2–/–;Vav3–/– mice [97]. This high degree of 
reciprocity in spite of the different experimental conditions and genetic backgrounds 
of Vav2Onc (this work) and Vav2–/–;Vav3–/– [97] mice shows that Vav2 is able to 
trigger this stem cell-like program in a signaling autonomous manner. This finding, 
together with the fact that Vav2 mediates its protumorigenic function catalytically 
and the recent observations indicating that the depletion of RAC1 restores chemo and 
radiosensitivity to hnSCC cell lines [193], suggest that the inhibition of the enzyme 
activity of this GEF could be a potential therapeutic avenue in a significant 
percentage of SCCs. This idea, which is at the heart of the study of most RHO GEFs 









mouse models [83]. To address this issue, we have generated cohorts of knock–in 
mice exhibiting varying amounts of Vav2 catalytic activity. With this strategy, we 
aimed at mimicking the usual conditions found with drug-based therapies in which 
the 100% inactivation of the target is hardly achieved. Using this approach we have 
found that effective therapeutic impacts can be obtained even under conditions in 
which some remaining GEF catalytic activity (Vav2L332A, ≈20% GEF activity) is 
preserved. Perhaps more importantly, these studies have unveiled the existence of 
therapeutic windows in which the homeostasis of the healthy tissues can be 
maintained. These preclinical results validate VAV2 as a potential therapeutic target 
to drive the differentiation and growth arrest of specific SCC subtypes. 
 
Vav2 regulates stemness in the hair follicle 
Understanding the physiological role of VAV2 in the homeostasis of the squamous 
epithelium will be of paramount importance for the design of the aforementioned 
potential therapeutic approaches. We have shown that Vav2 activity impinges on the 
epidermal fitness to adapt to challenges such as skin or hair regeneration, a 
phenotype that is associated with the abundance of EpSC and their responsiveness to 
activation cues. Interestingly, upregulated Vav2 activity leads to the perennial 
expansion of the EpSC reservoir while favoring a transcriptional status associated to 
quiescence. It should be noted that such quiescence is defined according to the 
transcriptomic profile of EpSC during telogen, and thus the term ‘quiescent’ can be 
misleading since the fact that these cells are not proliferating does not imply lack of 
cellular activity [153]. In fact, such quiescent cells upregulate a large transcriptional 
program involved in survival, the regulation of differentiation and proliferation, and 
the control of the metabolic status of the cell [153]. In terms of cellular functionality, 
our experiments have shown that this transcriptional endowments lead to a ready-to-
go state in the expanded population of Vav2Onc EpSC. 
In order to understand how upregulated Vav2 signaling is able to regulate 
epidermal stem cell homeostasis, here we have presented an EpSC transcriptomic 
time-course analyses. These studies have not only revealed how this GEF reshapes 
the EpSC transcriptome, but also provided valuable insights into the controversial 











shown that skin from young and aged mice have the same number of EpSC, 
assessment of how the passing of time affects their functionality has led to 
conflicting reports [175, 194, 195]. The lack of comprehensive time-course 
approaches specifically targeting the purified population of EpSC has precluded the 
elucidation of such controversy, and thus the molecular events that occur within the 
EpSC niche as it ages have remained hitherto largely unknown.  
Our in silico time-course study has revealed that around one third of the 
EpSC transcriptome is reconfigured throughout the first year of age. Although such 
figure is certainly influenced by disparities in the hair cycle phase among the 
differently aged EpSC, our data indicate that the overall contribution of the hair 
cycle-related genes to the dynamic patterns here described is rather limited. In fact, 
the overlap between our dynamic gene collection and the hair cycle-related genes 
[196] amounts to a mere 15% (data not shown). Interestingly, this collection of time-
sensitive transcripts doubles in size in the presence of hyperactive Vav2. Such 
amplification of transcriptional dynamism is an event that occurs late in the Vav2Onc 
EpSC lifetime, probably as a result of the dynamic remodeling that occurs at earlier 
stages.  
The Vav2-driven transcriptomic rewiring leads to the alteration of age-
specific transcriptional signatures, modifying the native functional enrichment of key 
time-driven biological processes. At a prime stage (18 days old), WT epidermal stem 
cells boost cell division and growth programs. Consistent with this, pathways 
associated with proliferation (E2F), stem cell activation (Hedgehog) and metabolic 
anabolism (Myc, MTOR) become strongly enriched. This occurs with the 
concomitant abrogation of quiescence-related signatures (TGFβ). Hyperactive Vav2 
favors stem cell quiescence even at these early stages, while increasing the 
transcriptional coordination between proliferation and anabolism pathways. By 
postnatal day 30 (mid-anagen) a drastic transcriptional rewiring takes place in WT 
EpSC, abolishing and promoting these cell proliferation and quiescence programs, 
respectively. This phenomenon, however, is largely dampened in the context of 
Vav2Onc signaling, where proliferation and activation signatures remain overly 
enriched. This is in agreement with the rest of evidence indicating that upregulated 
Vav2 signaling, while preserving the EpSC in a quiescent state, also favors EpSC 









After this initial dynamic burst, WT EpSC experience a phase of 
transcriptomic stillness during adulthood. Few genes display transcriptional 
fluctuations at this point, whose functional analyses reveal a modest enrichment in 
differentiation-related processes. In the Vav2Onc context, however, EpSC display the 
spurious deregulation of transcripts associated to ribosome biogenesis, signaling 
through RTKs and metabolic processes. In addition, Vav2Onc EpSC still preserve a 
highly quiescent transcriptional profile at this stage.  
The transcriptional calm in WT EpSC is lost by one year of age, when 
signatures associated to epidermal differentiation and stemness become markedly up- 
and downregulated, respectively. These data show the progressive deterioration of 
stemness-associated features, which is in agreement with the loss of clonogenic 
potential that other studies have reported in old EpSC [175]. We have also found the 
previously described age-driven transcriptional upregulation of the Jak-Stat and 
Notch signaling pathways [175]. However, our work has revealed that these 
phenomena are accompanied by an additional set of transcriptional events that had 
not been identified before. In our view, our increased resolution is due to the 
circumvention of some of the limitations of the preceding studies by i) performing a 
time-course approach instead of a two-point (young versus old) analysis, ii) 
including younger EpSC, and iii) isolating CD34+ Itga6+ bulge stem cells instead of 
using other less specific EpSC markers [175]. Importantly, this approach has allowed 
us to unveil that aged Vav2Onc EpSC upregulate transcriptional programs associated 
to epidermal morphogenesis and metabolic activity, thus suggesting that Vav2 
signaling might help preserve the fitness of the EpSC population. 
Further in silico analyses have revealed that this whole Vav2-induced 
conditioning of key EpSC signaling pathways and biological processes stems from 
the enhancement of transcriptional coordination. In pursuit of the factors driving 
such phenomenon, we have applied weighted correlation network algorithms to each 
coexpression cluster to identify its transcriptional hubs, i.e., the transcripts that are 
more closely related to every other transcript in terms of coexpression. These hubs 
constitute the heart of each coexpression cluster and, according to their 
transcriptional profiles, are in direct or close proximity to its transcriptional drivers. 











regulate transcription factors, or are even transcription factors themselves (data not 
shown). 
Even though most WT dynamic transcripts (84.6%) are also dynamic in 
Vav2Onc EpSC, we have encountered that only 26.5% of the WT transcriptional hubs 
occupy this position in Vav2Onc cells. This transcriptional hubs shift, which occurs 
throughout the entire time course we have analyzed, indicates that upregulated Vav2 
signaling emphasizes the activity of a particular set of transcriptional drivers that 
remodel the EpSC transcriptome. Interestingly, by focusing on those transcriptional 
hubs able to drive transcription directly, we have found that the Vav2-driven 
transcriptional program revolves around a collection of transcription factors strongly 
associated to the maintenance of quiescence within the EpSC niche. Although our 
data suggest the participation of both transcriptional and non-transcriptional 
mechanisms, how Vav2 controls the activity of these transcription factors will have 
to be further explored. In this regard, we are fully aware of the limitations of our in 
silico approach, which surely cannot capture the whole complexity of the regulatory 
networks governing the EpSC molecular landscape. Nevertheless, our data does 
provide sound evidence and directions to implement new multifaceted experimental 
approaches and lead to an unprecedented comprehension of the role of Rho exchange 
factors in the homeostasis of epidermal stem cells. 
 
Vav2 signaling in the skin: stemness in two flavors 
Collectively, these findings reveal that Vav2 signaling leads to the activation of 
divergent molecular programs in different epidermal cell compartments. While it 
promotes an undifferentiated and highly proliferative stem cell-like state in 
interfollicular keratinocytes, it favors quiescence within the epidermal stem cell 
niche. These programs are barely related, since the interfollicular Vav2-driven 
protumorigenic signature is not conserved in Vav2Onc EpSC, nor is the Vav2-
governed collection of EpSC-associated transcription factors functionally enriched in 
interfollicular Vav2Onc keratinocytes (data not shown). However, despite their 
apparent dissimilarity, both programs orbit around the same biological concept: 
stemness. Interestingly, cross-transcriptomic analyses aimed at this circumstance 









is driving a core of stemness-associated genes that is shared by interfollicular 
keratinocytes and epidermal stem cells (Figure XI). Such core is mainly involved in 
the regulation of DNA metabolism, replication and repair, and in the control of cell 
cycle progression (data not shown). 
Figure	LXX	
 
FIGURE XI. Vav2 signaling in the skin: stemness in two flavors. (A) Venn diagrams showing the 
overlap among the genes belonging to different stem cell-associated signatures that are enriched in the 
epidermis (left) and EpSC (right) of Vav2Onc mice. Red and blue colors represent positive and 
negative signature enrichments, respectively. *, number of overlapping genes between, at least, two 
transcriptional signatures. (B) Venn diagram showing the overlap between the stem cell-associated 
genes enriched in Vav2Onc epidermis and EpSC according to the data shown in panel A. EpSC, 
epidermal stem cell. 
 
This finding demonstrates that the two Vav2-directed molecular programs are 
based on common foundations, and thus exemplifies how different cells can funnel 
the same molecular essence into vastly different cellular programs. Understanding 
the underpinnings of these context-dependent engagements of Vav2 signaling will 
undoubtedly bring us one step closer to the rational design of strategies aimed at 
harnessing GEF activity. 
 
VAV2 belongs to a group of RHO GEFs with key roles in SCC carcinogenesis 
Besides our study of VAV2, recent data gathered from animal models, genome–wide 
expression analyses, and Pan–Cancer projects are beginning to illuminate new, and 
in some cases quite unsuspected roles for additional RHO GEFs [83, 129]. In such 
context, we have performed in silico analyses of SCC transcriptomic data in order to 
identify recurrent alterations in RHO GEF transcripts as an indicator of potential 
functional relevance in carcinogenesis. Such analyses have revealed that, in addition 











in these tumors. Importantly, we have found the same numbers of putative pro- 
(ECT2, FARP1, FGD6, TRIO, VAV2) and anti-tumorigenic (ARHGEF10L, ITSN2, 
KALRN, TIAM1, VAV3) GEFs in terms of differential expression and association 
with patient survival. This finding challenges the long-held notion that RHO GEFs 
are tumor driving proteins [83]. 
Our data indicate that both the putative pro- and anti-tumorigenic GEFs are 
transcriptionally regulated in a coordinated manner. It is important to emphasize that 
such transcriptional coordination is unrelated to their differential expression. 
Illustrating this, we have identified a group of GEFs that despite being strongly 
coexpressed, are not differentially expressed in SCC tumors. These coexpressions are 
not the result of cancer-associated genomic copy number variations either, but rather 
transcriptional events specifically targeting these loci. In keeping with this, 
coexpression among the members of these GEF clusters not only occurs in cancer 
settings, but also during normal keratinocyte differentiation. This is probably the 
reflection of coordinated but non-redundant GEF-mediated physiological programs 
that are harnessed by tumor cells. Consistent with this, such coordinated GEF 
clusters lie at the heart of large coexpression networks involved in the regulation of 
key processes for both stem and tumor cells. The elements driving these networks 
remain to be identified, although enrichment analyses of transcription factor binding 
sites have provided a series of candidate regulators. 
The putative protumorigenic function predicted by our in silico analyses for 
ECT2, FARP1, FGD6, TRIO and VAV2 has been biologically validated using SCC 
patient-derived cells in both histotypic cultures and xenograft experiments. These 
studies have also demonstrated that, although coordinated, these GEFs play non-
redundant functions as each of them conditions the tumorigenic features of SCC cells 
in a distinct manner. Importantly, these differential features become apparent in the 
context of xenografts experiments, but they are hardly unveiled by in vitro histotypic 
cultures. This constitutes yet another illustrative example of how narrowing GEF 
studies to in vitro settings, as has occurred historically, severely cripples our 
understanding of the true biological role of these proteins in cancer and other 
physiopathological processes.  
It should be noted that the immunocompromised Vav1–/–;Vav2–/–;Vav3–/– 









marginal levels of T-lymphocytes (data not shown). This means that tumor growth in 
this setting is not only the result of the intrinsic proliferative capability of the grafted 
tumor cell, but also of its immunogenic potential. Importantly, this feature allows our 
experimental model to mimic more faithfully the scenario in which human tumors 
grow and circumvents one of the major drawbacks of immunodeficient mouse 
models, i.e., that the lack of functional immune system hampers both disease 
modeling and clinical translation [197]. 
According to our experiments, TRIO could very well be considered the 
Achilles heel of the patient-derived SCC cells. Despite the fact that this protein does 
not seem to be as intimately associated to the control of cell differentiation as other 
protumorigenic GEFs, its downmodulation stunts tumor cell growth in vivo to an 
extent that is unmatched by any of the other exchange factors tested. This phenotype 
is much stronger than the one revealed by in vitro studies, thus suggesting that the 
tumor microenvironment might be playing a determinant role here. Consistent with 
this, previous studies have shown that TRIO mediates the proliferative response to 
mitogens in several cancer cells [198]. 
We have found that patient-derived SCC cells are also strongly dependent on 
ECT2 activity in order to maintain both their proliferation potential and their 
undifferentiated state. This observation could be expected to some extent, since this 
GEF is an essential component of the molecular apparatus responsible for cell cycle 
progression and cytokinesis [114]. Nevertheless, ECT2 has also been reported to 
impinge on cancer cell growth through alternative mechanisms different from direct 
control of cell division, including the regulation of the ribosome biogenesis [113]. 
Although the precise functions of ECT2 in SCC cells will have to be addressed in the 
future, the knockdown of this GEF in our patient-derived cells results in a 
conspicuous enucleation defect, thus suggesting its implication in the differentiation-
driven processes that lead to nuclear degradation in keratinocytes [199].  
On the other side of the spectrum, FGD6 has proven to be a prototypical case 
of a gene with potential therapeutic interest according to in vitro studies that, when 
tested in vivo, has led to only marginal effects. This suggests that whatever 
deficiency the abrogation of FGD6 is originating in SCC cells cultured in vitro, it is 
somehow overcome in vivo. In our view, this does not necessarily rule out the 











suggest that in order to do so it might require the presence of additional oncogenic 
events. It should also be noted that we have not found increased levels of FGD6 in 
any of our SCC cell lines, which could indicate that they are not as dependent on the 
activity of this GEF. Alternatively, the catalytic specificity could also be a relevant 
factor, since the two GEFs that have displayed mild phenotypes in our in vivo 
experiments, FGD6 and FARP1, are the ones involved in the activation of CDC42 
GTPase, whose role in carcinogenesis is still unclear [83]. In any case, whether some 
of these elements are accountable for our findings will have to be further explored in 
the future. 
Taken together, these experiments have materialized the notion that VAV2 is 
but one member of a group of RHO exchange factors that govern key processes 
involved in SCC carcinogenesis. Importantly, our in vivo data shows that, besides 
VAV2, TRIO and ECT2 also constitute appealing candidates for the exploration of 
new therapeutic avenues against hnSCC. Since our immunohistochemical and 
promoter activation assays have shown that these GEFs control different distal 
effectors (data not shown), combined therapies targeting several of these GEFs are, 
theoretically, also practicable. While we have already proved the existence of 
therapeutically safe windows for VAV2 inhibition, this will require analog studies in 
the case of TRIO, ECT2 and their potential combined inhibition. One should bear in 
mind, however, that this is just the first step in the long journey towards RHO GEF-
based therapies. The major roadblock to reach that goal lies probably right ahead, 
since the biochemical properties of exchange factors makes the design of efficient 
pharmacologic inhibitors a challenging task [83, 200]. Nevertheless, this obstacle is 
not insurmountable and our data provides a new rationale to focus novel drug design 
strategies on particular GEFs. 
Unlike the preceding findings, the observation that some RHO GEFs 
(ARHGEF10L, ITSN2, KALRN, TIAM1, VAV3) are consistently downregulated in 
SCC tumors was a rather unanticipated discovery. Our xenograft SCC model has 
shown that such transcriptional downmodulation is linked to tumor suppressor-like 
functions for ITSN2, KALRN and VAV3. Except for VAV3, these functions are not 
detected in vitro, which suggests the implication of the tumor microenvironment. On 
the other hand, neither in vitro nor in vivo models have revealed alterations in SCC 









several causes. Firstly, tumor suppression functions might manifest in a way not 
readily revealed by our models, as can be exemplified by the case of TIAM1. In 
keeping with a tumor-suppressive function, the deficiency of this GEF has already 
been shown to lead to the exacerbation of SCC malignancy in vivo [98]. However, 
this is accompanied by a counterintuitive decrease in tumor multiplicity and size 
[98]. Probably, our models are an unsuitable experimental approach to unveil such 
paradoxical anti-tumorigenic functions. Another possible explanation for the lack of 
phenotype of these GEFs is that their downmodulation has to concur with the 
alteration of additional signaling molecules, either within or without the RHO 
signaling cascade. Lastly, it should also be considered that in the case of patient-
derived SCC cells, the expression levels of some of these GEFs might be natively too 
low to induce further effects by additional shRNA-based downmodulation. Our 
experimental plan will continue with the ectopic expression of these GEFs in order to 
shed light on these lingering issues. 
In any case, without undervaluing the inherent relevance of proving that RHO 
GEFs can also play tumor suppressor-like roles, it is worth noting that the potential 
therapeutic exploitability of this finding is rather limited, as neither the 
pharmacologic nor the genetic induction of GEF activity is currently a viable 
therapeutic option. Perhaps more importantly, what this finding demonstrates is that 
therapies directed towards protumorigenic GEFs have to be exquisitely specific. This 
is of paramount relevance since our data shows that off-target GEF inhibition can 
result in a negative therapeutic impact. 
 
The mechanisms underlying RHO GEF idiosynchrasy: a puzzle to be solved 
The aforementioned findings show that from a shared molecular commitment, i.e., 
the activation of RHO GTPases, GEFs are able to elicit different and even 
antagonistic responses in the context of SCC carcinogenesis. This inevitably raises 
the most fundamental question: what differences in their activity as exchange factors 
account for such functional divergence?  
Probably the most straightforward explanation would be that each of these 
GEFs activated different RHO GTPases. However, based on data from both our lab 











sufficient to explain our observations. For instance, VAV3 (anti-tumorigenic) and 
VAV2, ECT2 and TRIO (pro-tumorigenic) activate both RHOA and RAC1 GTPases 
(Figure XII-A). Similarly, ITSN2 (anti-tumorigenic) and FGD6 (pro-tumorigenic) 
share catalytic activity towards CDC42 (Figure XII-A). And even more puzzling, 
despite the fact that RAC1 has been unmistakably linked to protumorigenic functions 
in SCC [83], the two RAC1-specific GEFs KALRN and TIAM1 display 
antitumorigenic profiles (Figure XII-A). This puts in evidence that the catalytic 
specificity is a poor predictor of GEF function. 
Figure	LXXI	
 
FIGURE XII. Current evidence on RHO GEF catalytic specificity, subcellular localization and 
interactome. (A) Ternary plot showing the catalytic specificity of the RHO GEFs that are up- (red) 
and downregulated (blue) in hnSCC. The affinity for a given GTPase is represented by the proximity 
to the corresponding coordinates. (B) Radar plots showing the subcellular location of the RHO GEFs 
that are up- (red) and downregulated (blue) in hnSCC. N, nucleus; A, actin cytoskeleton; FA, focal 
adhesions; C, cytosol; PM, plasma membrane. (C) Protein-protein interaction network of the RHO 
GEFs that are up- (red) and downregulated (blue) in hnSCC. Shared interacting proteins among two 
upregulated, two downregulated and two differentially regulated GEFs are highlighted in light red, 
light blue and light green, respectively. The data represented in all panels was obtained from 









GTPase activation at different subcellular locations can also trigger various 
cellular responses [201, 202]. However, except for the localization of ECT2 in the 
nucleus, pro- and anti-tumorigenic GEFs share quite overlapping localizations across 
the cytosol, plasma membrane, actin cytoskeleton and focal adhesions (Figure XII-
B). Therefore, these data indicate that the subcellular localization does not correlate 
with the idiosyncratic behavior of GEFs in SCC carcinogenesis. 
As these evidences seem to suggest, linking the carcinogenesis-associated 
role of each GEF with its molecular function will probably require the investigation 
of its proximal effectors. Consistent with this, previous studies have shown that 
GEFs with the same catalytic specificity can elicit antagonistic cellular responses 
through the activation of different effectors [203]. In this regard, the analysis of 
publicly-available proteomics data on the interactome of RHO GEFs shows that the 
exchange factors we have studied only share about 15% of their interacting proteins 
(Figure XII-C). This is a clear indicator that, although they might coincide in 
catalytic specificities and subcellular locations, these GEFs are triggering vastly 
different signaling programs.  
Regardless of the mechanisms underlying their idiosynchrasy, we should be 
aware of the fact that the approach we have used to identify RHO GEFs with 
potentially relevant functions in SCC tumorigenesis is exclusively based on 
transcriptomic data. This means that our findings still need to be complemented by 
studies assessing other potential non-transcriptional mechanisms involved in the 
regulation of RHO GEF activity. Intriguingly, DNA mutation does not seem to be 
one of them, as neither the pro- nor the anti-tumorigenic GEFs we have identified are 
significantly mutated in SCC tumors (data not shown). Why tumor cells favor 
transcriptional deregulation over DNA mutation in order to manipulate GEF activity 
is still to be understood. One possible explanation might lie in the flexibility intrinsic 
to gene expression control as opposed to the irreversible nature of genetic lesions. 
Perhaps the constitutive deregulation of GEFs throughout all stages of SCC 
carcinogenesis might not be as beneficial as the fine-tuned transcriptional modulation 
of their activity. Alternatively, genetic mutations might lead to conformations that 
are not as effective inducing tumorigenesis as a consequence of the impairment of 
non-catalytic GEF functions. Paralleled to these possibilities, the RAS-based G12 or 











been used to model RAC1 activation in laboratories, are hardly found in human 
tumors [83, 86]. Instead, the fast-cycling P29S mutation, which is more flexible and 
still allows transition between the GTP- and GDP-bound states, is the one most 
commonly occurring [83, 86]. This supports the idea that, unlike the case of RAS 
GTPases, blind constitutive activation of RHO signaling might not be the most 
efficient protumorigenic avenue. 
 
Vav2 and Vav3: friends and foes 
The data presented here have made one conclusion redundantly clear: instead of 
playing cooperative roles as previous evidences seemed to indicate [97], VAV2 and 
VAV3 have antagonistic functions in the context of SCC carcinogenesis. This is a 
rather unexpected behavior for two GEFs that share 51.8% and 69.1% of sequence 
identity and similarity, respectively. In fact, this phenomenon seems to be cell 
lineage-specific as Vav2 and Vav3 do play cooperative roles in other carcinogenic 
contexts such as breast adenocarcinoma [128, 204]. In addition, we have found that 
these GEFs also play cooperative roles in the EpSC context, since the reversal of the 
defects elicited by Vav2Onc in EpSC requires the elimination of both Vav2 and Vav3.  
This apparent paradox in the roles of Vav2 and Vav3 in the epidermis can 
be attributed to several possible causes. On the one hand, one straightforward 
explanation is that the spectra of Vav2 and Vav3 effectors differ greatly between 
EpSC and interfollicular keratinocytes, allowing their cooperation in the former cell 
compartment. On the other hand, the possibility that such cooperation does not occur 
within the same cellular compartment cannot be formally ruled out. Although our 
skin xenograft experiments have shown that the hair-follicle-associated phenotype 
driven by Vav2 is keratinocyte autonomous, they are unable to resolve which 
epidermal cell populations are contributing to it. As such, we cannot neglect the 
possibility that other multipotent cell populations from the hair follicle might be 
participating in the phenotype seen in bulge EpSC. If this were the case, the 
redundancy between Vav2 and Vav3 signaling programs in any of these surrounding 
cell compartments could explain the lack of EpSC phenotype seen in Vav2-deficient 
mice. This hypothesis can be even extended to fibroblasts, since skin xenograft 









of hair follicles and epidermal inclusion cysts. As cooperation between Vav2 and 
Vav3 in mouse fibroblasts has already been reported [205], it is possible that the 
expression of Vav3 in the dermal compartment might be able to alleviate the 
deficiency of Vav2 in the EpSC niche in a paracrine fashion. 
In any case, further work will have to be devoted to the characterization of 
Vav2 and Vav3 effectors in different cellular contexts in order to fully understand 
































Based on the preceding findings, the research presented in this Ph.D. thesis indicates 
that: 
 
1. VAV2 drives a signaling-autonomous molecular program involved in the 
maintenance of a stem cell-like proliferative and undifferentiated state in both 
cutaneous and oral squamous epithelia. This program is triggered 
catalytically through the activation of RAC1 and RHOA GTPases. 
 
2. The VAV2-driven molecular program is frequently engaged by malignant 
and premalignant cells of the squamous epithelium, promoting tumor 
progression and leading to poor prognosis. The tumorigenic fitness of full-
blown SCC tumor cells is highly sensitive to VAV2 activity. 
 
3. Inhibition of Vav2 catalytic activity prevents SCC tumor formation and 
progression. There are therapeutic windows where this effect can be achieved 
without triggering the side effects associated to the physiological role of this 
exchange factor. 
  
4. Vav2 regulates the abundance, activity and responsiveness of hair follicle 
bulge epidermal stem cells. This function is at least partially coordinated with 
Vav3. 
 
5. Vav2 controls the dynamic configuration of the EpSC transcriptome across 
time. This Vav2-governed transcriptional program impinges on the regulation 
of EpSC homeostasis and quiescence.  
 
6. In addition to VAV2, the RHO exchange factors ECT2, FARP1, FGD6 and 
TRIO also contribute to the fitness of hnSCC tumors. These protumorigenic 
roles are non-redundant. 
 
7. The RHO exchange factors ITSN2, KALRN and VAV3 play anti-
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Data, figures and research achievements are thoroughly described in the pages that 
compose this thesis with a double intention: the proper conveyance of such findings 
to the scientific and academic communities, and the preservation in time and 
memory of the essence of my doctorate. Although hopefully proficient at the former, 
this dissertation will inevitably fail at the latter, as a doctorate is a long journey of 
both profesional and personal metamorphosis that cannot be captured by merely 
displaying the goals eventually attained. A journey is not the finishing line, it is the 
journey itself, and that is not only a story of data, it is also a story of people. These 
last pages are for them. 
I will not begin by saying thank you, but I am sorry, for I am aware that many 
people whose name is not included here should receive a more explicit recognition. 
Be sure that this is not lack of consideration or gratefulness, both of which I have, 
but are just flaws of this Ph.D. student who, thorough in his acknowledgements as he 
has tried to be, will surely not be able to bring up all those people who were of 
invaluable assistance, in one way or another, along these years. Let me assure you 
that what is written here is also for you. 
English is undoubtedly the language of science, which is the reason why I 
chose it to transmit all the scientific matters contained in this thesis. And although it 
would also be a perfectly valid tool to convey my akcnowledgements, parece que es 
la lengua materna la que más se acerca al corazón o al alma, cualquiera que sea el 
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escribir estas líneas finales. Como consecuencia, muchas veces estas hojas 
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que parezcan los contenidos de este libro, vosotros estáis en ellos, y que lo único que 
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RESUMEN DE LA INTRODUCCIÓN 
El epitelio escamoso es uno de los más abundantes del cuerpo humano, el cual cubre 
multitud de órganos y tejidos. La epidermis, en la piel, y las mucosas masticatoria y 
especializada, en la cavidad oral, son dos claros representantes del mismo. Estos 
epitelios están compuestos por un conjunto de células apiladas, denominadas 
queratinocitos, que se organizan en una serie de capas o estratos.  Dichas estructuras 
se encuentran sometidas a un proceso de renovación constante, en el que los 
queratinocitos más maduros, situados en el estrato más externo, se desprenden 
continuamente y son reemplazados por células provenientes de las capas más 
internas. Esta renovación está sustentada por las células madre del epitelio, las cuales 
se dividen y autoperpetúan para responder a esta demanda y mantener la homeostasis 
tisular. Tales células madre se clasifican en diferentes tipos que se localizan en 
regiones muy concretas del epitelio, bien en su parte más basal o, en el caso de la 
epidermis, alojadas en el folículo piloso. De entre todas ellas, la célula madre 
epidérmica (EpSC) por excelencia es aquella que reside en la protuberancia (o bulge) 
del folículo piloso, una célula de división infrecuente que es capaz de regenerar todos 
los linajes epiteliales de la epidermis. 
La acumulación de eventos oncogénicos en el epitelio escamoso conduce a su 
transformación tumoral y al desarrollo del carcinoma de células escamosas (SCC). El 
SCC cutáneo (cSCC) es el segundo cáncer epitelial más frecuente de la piel y está 
generalmente asociado a la exposición a la radiación UV. Por otro lado, el SCC que 
surge a partir del epitelio oral se engloba dentro de los cánceres de cabeza y cuello 
(hnSCC), y suponen sexto tipo tumoral más frecuente. Estos tumores están asociados 
al consumo de tabaco, alcohol y a infecciones por el virus del papiloma humano. La 
incidencia de ambos cánceres se encuentra actualmente en aumento, y si bien la tasa 
de supervivencia a 5 años del cSCC supera el 95%, este porcentaje se sitúa en el 50–
60% en el caso del hnSCC. La reciente caracterización molecular de estos tumores 
ha desvelado que los distintos factores oncogénicos que contribuyen a su origen 
convergen en una serie de alteraciones genómicas y transcriptómicas. Dichas 
alteraciones afectan a genes vinculados a al control del ciclo celular, la transducción 
de señales, la diferenciación celular, la regulación epigenética y la señalización a 
través de las GTPasas de la familia RHO. Puesto que aún se conoce muy poco acerca 
de cómo la señalización a través de dichas GTPasas participa en la carcinogénesis 
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del epitelio escamoso y, sobre todo, de si su modulación puede emplearse como una 
nueva herramienta terapéutica, hemos decidido enfocar el presente trabajo doctoral 
en tales cuestiones. 
Las GTPasas de la familia RHO son pequeñas proteínas que controlan una 
serie de procesos fundamentales para la biología celular, incluyendo el control del 
citoesqueleto, la migración, la proliferación, la diferenciación y la supervivencia. 
Estas proteínas funcionan como interruptores moleculares, alternando entre una 
conformación activa y una inactiva como respuesta a un amplio grupo de señales 
moleculares. Los agentes encargados de catalizar la activación de estas GTPasas en 
presencia de señales activadoras reciben el nombre de factores de intercambio de 
nucleótido de guanina (GEFs), mientras que aquellos que desempeñan la acción 
opuesta son denominados proteínas activadoras de GTPasas (GAPs). RAC1, RHOA 
y CDC42 son las GTPasas mejor caracterizadas dentro de la familia RHO, las cuales 
desempeñan papeles fundamentales en la homeostasis de las células madre del 
epitelio escamoso, en especial RAC1. Evidencias derivadas de muestras de pacientes 
y de distintos modelos animales han demostrado que dicha GTPasa cuenta con un rol 
inequívocamente protumorigénico en la carcinogénesis del SCC, mientras que la 
función de RHOA y CDC42 parece ser mucho más dependiente del contexto tumoral 
particular. 
A pesar de la implicación de las GTPasas de la familia RHO en el desarrollo 
tumoral, sus propiedades bioquímicas las convierten en proteínas difícilmente 
abordables desde el punto de vista farmacológico, lo cual dificulta su explotación 
con fines terapéuticos. No obstante, puesto que su activación es dependiente de la 
actividad GEF, el trabajo expuesto en esta tesis doctoral se ha centrado en los 
factores de intercambio de nucleótido de guanina como mediadores clave de la 
señalización por las GTPasas RHO cuya actividad sí puede ser modulada 
farmacológicamente. Si bien existen más de 70 GEFs en la célula, estudios previos 
en líneas celulares y modelos animales sugieren que Vav2 representa un candidato 






Por lo anteriormente expuesto, esta tesis se ha dirigido a: 
 
1. La caracterización de la implicación del GEF Vav2 en la carcinogénesis del 
carcinoma de células escamosas cutáneo y de cabeza y cuello. 
 
2. La evaluación del valor terapéutico de la inhibición catalítica de Vav2 para el 
tratamiento del carcinoma de células escamosas. 
 
3. El descubrimiento de las funciones fisiológicas de Vav2 asociadas al 
mantenimiento fisiológico del epitelio escamoso. 
 
4. La identificación y validación de otros GEFs con funciones relevantes en la 
formación y progresión del carcinoma de células escamosas. 
 
 
RESUMEN DE LOS RESULTADOS 
VAV2 induce la proliferación regenerativa y el mal pronóstico del carcinoma de 
células escamosas 
El análisis de muestras de cSCC y hnSCC derivadas de pacientes ha revelado que 
VAV2 se encuentra frecuentemente sobreexpresado en estos tipos tumorales y que 
sus niveles de expresión están asociados con la supervivencia de los pacientes. Con 
objeto de evaluar cuál es el impacto fisiopatológico de tal ganancia de función de 
VAV2, hemos empleado un modelo murino knockin que expresa una versión 
hiperactiva de este GEF (denominada Vav2Onc). Estos ratones desarrollan hiperplasia 
en distintos epitelios escamosos, incluyendo al epidermis, el paladar y la lengua, 
caracterizada por la expansión de células progenitoras inmaduras con altas tasas de 
proliferación. La presencia de lesiones genéticas adicionales conduce a estos ratones 
al desarrollo de tumores de manera temprana, que además son más abundantes y de 
mayor tamaño y malignidad, con una mayor frecuencia de SCCs infiltrantes en 
estadio avanzado. Tales hallazgos indican que VAV2 induce un estadio 




Puesto que VAV2 se expresa de manera prácticamente ubicua en el 
organismo, hemos implementado cultivos tridimensionales in vitro de queratinocitos, 
humanos y murinos, con objeto de confirmar que el fenotipo inducido por este GEF 
en el epitelio escamoso radica en los tales células. Estos modelos experimentales han 
permitido además establecer que VAV2 gobierna dicho programa protumorigénico 
de manera catalítica a través de la activación de las GTPasas RAC1 y RHOA. 
La caracterización del transcriptoma epidérmico de los ratones Vav2Onc ha 
desvelado que este GEF dirige un amplio programa transcripcional implicado en el 
control de la proliferación, diferenciación y procesos asociados a la respuesta inmune 
y a la regulación metabólica. El análisis de las proteínas que median dicho programa 
transcripcional ha  conducido a los reguladores c-Myc, Yap, AP1 y E2F, cuya 
actividad es inducida por Vav2. De entre ellos, la señalización a través de c-Myc y 
YAP es fundamental para la activación de los procesos de proliferación e 
indiferenciación controlados por dicho GEF. Todo ello hace que la ganancia de 
función de Vav2 en queratinocitos favorezca un perfil transcripcional semejante al 
presente en progenitores y células madre epidérmicas. Tal perfil transcripcional se 
encuentra también altamente conservado en tumores humanos de cSCC y hnSCC, y 
funciona como elemento predictor de la supervivencia del paciente. La aplicación de 
una serie de algoritmos bioinformáticos ha permitido destilar esta asociación entre el 
programa molecular gobernado por Vav2 y la supervivencia del paciente en una 
firma transcripcional de alto valor pronóstico compuesta por 41 genes. 
 
Validación preclínica del valor terapéutico de la actividad catalítica de Vav2 
Con objeto de evaluar la relevancia de la actividad de VAV2 en las propiedades 
tumorales del SCC, hemos reprimido los niveles de expresión de este GEF en líneas 
celulares derivadas de pacientes. Tanto en cultivos tridimensionales in vitro, como en 
modelos de xenotrasplante ortotópico en ratones inmunodeficientes, la pérdida de 
función de VAV2 conduce a una represión de la capacidad proliferativa y a una 
inducción de la diferenciación en células tumorales. Este hallazgo se ha trasladado a 
un contexto terapéutico mediante la generación de una serie de modelos murinos que 
presentan distintos niveles de actividad catalítica de Vav2. De esta manera se 
mimetiza el tratamiento con fármacos, los cuales rara vez consiguen bloquear la 
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actividad de sus dianas en su totalidad. Así, hemos encontrado que reducir la 
actividad catalítica de Vav2 al ~20% confiere protección frente al desarrollo y la 
progresión del SCC. Sin embargo, esa actividad catalítica residual es suficiente para 
prevenir la aparición de efectos secundarios asociados a las funciones fisiológicas de 
Vav2 en el sistema cardiovascular. Este hallazgo demuestra que existen ventanas 
terapéuticas de inhibición de Vav2 que permiten obstaculizar el desarrollo tumoral 
sin afectar a la homeostasis de los tejidos sanos. 
 
Vav2 regula la actividad de las células madre epidérmicas en el folículo piloso 
Análisis adicionales de los ratones Vav2Onc han demostrado que al margen de su rol 
en carcinogénesis, Vav2 desempeña funciones fundamentales en el contexto 
fisiológico de la epidermis. Tanto la regeneración de la piel ante heridas como la 
regeneración del pelo ante la depilación ocurren de manera acelerada en ratones 
dotados de la versión hiperactiva de Vav2. Este fenotipo está asociado a una mayor 
abundancia de células madre epidérmicas en la protuberancia del folículo piloso 
(EpSC), que además presentan una mayor capacidad de respuesta frente a estímulos 
activadores. La realización de trasplantes de células epidérmicas provenientes de 
ratones Vav2Onc a ratones desnudos inmunodeficientes ha permitido verificar que este 
fenotipo es autónomo de este tipo celular. 
Todas estas observaciones se revierten en el caso de los ratones Vav2–/–;Vav3–
/–, que presentan una regeneración más lenta de piel y pelo y un menor número y 
capacidad de respuesta de las EpSC. La contraposición entre los fenotipos de las 
EpSC dotadas de Vav2 hiperactivo y aquellas carentes de Vav2 y Vav3 ha sido 
caracterizada transcriptómicamente con el fin de elucidar el programa molecular 
gobernado por Vav2 en este contexto. Dichos análisis han desvelado que este GEF 
controla la expresión de un amplio número de genes implicados en pluripotencia a la 
par que establece un perfil transcripcional asociado a quiescencia. Este hecho, unido 
a que el fenotipo inducido por Vav2Onc se mantiene en el tiempo, ha conducido a la 
ampliación del análisis transcriptómico para abarcar EpSC comprendidas entre 18 
días y 1 año de edad. El tratamiento de estos datos con diversos algoritmos 
bioinformáticos ha permitido evaluar cómo varía el transcriptoma de las EpSC con el 
paso del tiempo, así como la influencia de Vav2 en dicho fenómeno. Esto ha 
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revelado que el 31.9% de los mRNA de las EpSC presentan un comportamiento 
dinámico en el tiempo, puesto que su expresión varía con la edad. La hiperactivación 
de Vav2 se traduce en un marcado incremento de dicho dinamismo transcripcional, 
tanto por la remodelación de los patrones transcripcionales de genes que son 
dinámicos en condiciones nativas, como por la inducción de nuevos genes 
dinámicos. Esta remodelación transcripcional dirigida por Vav2 altera, de manera 
específica en función de la edad, el enriquecimiento funcional de procesos biológicos 
y rutas de señalización esenciales para la homeostasis de las células madre 
epidérmicas. En particular, hemos encontrado que la actividad de Vav2 coordina una 
serie de genes y procesos asociados a proliferación, diferenciación y metabolismo 
anabólico que permite enriquecer y perpetuar la población de células madre sin 
obstaculizar su activación en presencia de estímulos. 
Con objeto de investigar cuáles son los agentes mediadores de esta 
remodelación transcriptómica inducida por Vav2, hemos identificado 
computacionalmente aquellos genes que se encuentran en el núcleo transcripcional 
de los patrones de expresión gobernados por Vav2Onc. Estos análisis, unidos a la 
evaluación de sitios de unión de factores de transcripción, han permitido descubrir 
que Vav2 favorece la activación de un grupo de factores de transcripción 
específicamente asociados al mantenimiento de la quiescencia en las células madre 
epidérmicas. 
 
Más allá de VAV2: la familia de intercambiadores de nucleótido de las GTPasas 
RHO en la carcinogénesis del epitelio escamoso 
La caracterización de los roles fisiopatológicos desempeñados por VAV2 en la 
homeostasis y la carcinogénesis del epitelio escamoso nos ha conducido a evaluar si 
tales funciones son exclusivas de este GEF o, por el contrario, existen otros 
miembros de la familia de factores de intercambio de nucleótido que desempeñan 
papeles similares. El análisis de datos transcriptómicos de muestras de hnSCC 
derivadas de pacientes ha demostrado que, además de VAV2, ECT2, FARP1, FGD6 
y TRIO se encuentran frecuentemente sobreexpresados en el tejido tumoral. 
Inesperadamente, también hemos hallado que un número similar de GEFs, 
incluyendo a ARHGEF10L, ITSN2, KALRN, TIAM1 y VAV3, se encuentra 
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transcripcionalmente reprimido. Esta expresión diferencial correlaciona en muchos 
casos con el pronóstico del paciente: mientras que los GEFs sobreexpresados están 
asociados a un peor pronóstico, lo contrario ocurre en el caso de los reprimidos. 
Diversos análisis bioinformáticos nos han permitido descubrir que los 
cambios en la expresión de este grupo de GEFs ocurren de manera coordinada, tanto 
en el contexto tumoral como durante la diferenciación de queratinocitos sanos. Este 
fenómeno es relevante desde el punto de vista pronóstico, pues la regulación 
conjunta de estos GEFs se asocia fuertemente con la supervivencia del paciente. Esta 
coordinación transcripcional se encuentra enmarcada dentro de grandes redes de 
coexpresión que aglutinan genes involucrados en la regulación de procesos 
fundamentales para la tumorigénesis del epitelio escamoso, tales como la interacción 
con la matriz extracelular, el potencial morfogénico, la proliferación y la 
diferenciación. 
Con objeto de validar biológicamente el potencial protumorigénico de los 
GEFs que se encuentran sobreexpresados en hnSCC, hemos recurrido a nuestra 
colección de células tumorales derivadas de pacientes. La represión de los niveles de 
expresión de dichos GEFs obstaculiza la proliferación e induce la diferenciación de 
estas células en cultivos tridimensionales in vitro. La implantación de las mismas en 
la cavidad oral de ratones inmunodeficientes ha permitido demostrar que, además de 
VAV2, ECT2 y TRIO desempeñan una función protumorigénica a la cual las células 
tumorales presentan un alto grado de dependencia in vivo. Dichas funciones están 
mediadas por mecanismos no redundantes dirigidos por cada GEF. 
La elucidación del potencial papel antitumorigénico de los GEFs que se 
encuentran transcripcionalmente reprimidos en SCC se ha llevado a cabo en modelos 
celulares dotados de diferentes cargas mutacionales. Esta estrategia experimental ha 
permitido desvelar que, en presencia de lesiones oncogénicas adicionales, la 
represión de VAV3 favorece el crecimiento hiperplásico de las células escamosas in 
vitro. Asimismo, hemos descubierto que la represión de tanto VAV3 como ITSN2 y 
KALRN fomenta el crecimiento tumoral in vivo. De acuerdo con esto, la aplicación 
de protocolos de carcinogénesis química a ratones carentes de Vav3 ha demostrado 
que la pérdida de función de este GEF conduce al desarrollo de un número 




En conjunto, estos descubrimientos demuestran que los factores de 
intercambio de nucleótido de guanina de las GTPasas de la familia RHO desempeñan 
papeles clave tanto en al inducción como en la represión del carcinoma de células 
escamosas. La modulación de su actividad, por tanto, constituye un recurso potencial 




1. VAV2 dirige un programa molecular autónomo implicado en el 
mantenimiento de un estado proliferativo e indiferenciado en los epitelios 
escamosos cutáneo y oral. La activación de dicho programa ocurre de manera 
catalítica mediante la activación de las GTPasas RAC1 y RHOA. 
 
2. El programa molecular dirigido por VAV2 está frecuentemente activado en 
células malignas y premalignas del epitelio escamoso, favoreciendo la 
progresión tumoral y conduciendo a un mal pronóstico. El potencial 
tumorigénico del carcinoma de células escamosas está fuertemente 
condicionado por la actividad de VAV2. 
 
3. La inhibición de la actividad catalítica de Vav2 previene el desarrollo tumoral 
del carcinoma de células escamosas. Existen ventanas terapéuticas en las que 
dicho efecto se puede inducir sin ocasionar los efectos secundarios asociados 
a las funciones fisiológicas de este GEF. 
 
4. Vav2 regula la abundancia, actividad y capacidad de respuesta de las células 
madre epidérmicas alojadas en la protuberancia del folículo piloso. Esta 
función está parcialmente coordinada con Vav3. 
 
5. Vav2 controla circuitos transcriptómicos de las EpSC y su reconfiguración 
dinámica a lo largo del tiempo. Dicho programa transcripcional regula la 




6. Junto a VAV2, los RHO GEF ECT2, FARP1, FGD6 y TRIO contribuyen al 
potencial tumorigénico del carcinoma de células escamosas. Dicha función 
protumorigénica está mediada por mecanismos no redundantes. 
 
7. Los RHO GEF ITSN2, KALRN y VAV3 desempeñan funciones 
antitumorigénicas en el desarrollo del carcinoma de células escamosas. 
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